Curtis Pettaway, M.D.

Peer-Reviewed Articles

1. Miyagi, H, Yu, X, Peak, T, Dhillon, J, Le, C, Wang, X, Yoder, SJ, Marchion, D, Lu, X, Pettaway, CA, Segura, CM, Zhang, C, Roman Souza, G, Yu, A, Zemp, L, Spiess, PE, Chahoud, J. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 40044748.
2. Jackson, J, Johns, AC, Campos Clemente, L, Manuel, C, Qiao, W, Lu, W, Khan, KB, Solis Soto, LM, Chahoud, J, Rao, P, Campbell, M, Pettaway, CA, Millward, NZ. Tissue Factor Expression in Penile Squamous Cell Carcinoma. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228204.
3. Hatoum F, Souza GR, Johnson J, Miller J, Fazili A, Pettaway CA, Campbell MT, Neubauer R, Johns A, Mizelle SR, Kim Y, Chadha J, Zhang J, Jameel G, Oschmann E, Dhillon J, Moscu A, Janeway R, Harris W, Lu X, Spiess PE, Chahoud J. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma. Future Oncol:1-9, 2025. e-Pub 2025. PMID: 41163621.
4. Jackson JC, Johns AC, Campos Clemente L, Manuel CM, Qiao W, Lu W, Khan K, Solis Soto LM, Chahoud J, Rao P, Campbell MT, Pettaway CA, Zacharias NM. Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease. Cancers (Basel) 17(21), 2025. e-Pub 2025. PMID: 41228204.
5. Cooper, S, Nicholson, S, Crook, J, Watkin, NA, Pettaway, CA, Barber, J, Mitra, AV, Woodley, O, Millin, A, Hall, E, Pathmanathan, AU, Penegar, S, Burnett, S, Spiess, PE, Miles, E, Hoffman, K, Yang, H, Tree, A. Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT). International Journal of Radiation Oncology Biology Physics 123(1):171-182, 2025. e-Pub 2025. PMID: 40180061.
6. Kibbi, N, Owen, JL, Worley, B, Alam, M, Wang, JX, Harikumar, V, Downing, MB, Aasi, SZ, Aung, PP, Barker, CA, Bolotin, D, Bordeaux, JS, Cartee, TV, Chandra, S, Cho, NL, Choi, JN, Chung, KY, Cliby, W, Dorigo, O, Eisen, DB, Fujisawa, Y, Golda, N, Halfdanarson, TR, Iavazzo, C, Jiang, SI, John, EM, Kanitakis, J, Keimig, EL, Khan, A, Linos, E, Kim, JY, Kuzel, TM, Lawrence, N, Leitao, M, Maclean, AB, Maher, IA, Mittal, BB, Nehal, KS, Ozog, DM, Pettaway, CA, Rajan, N, Ross, JS, Rossi, AM, Servaes, S, Solomon, MJ, Thomas, V, Tolia, M, Voelzke, BB, Waldman, AH, Wong, MK. Recommended guidelines for screening for underlying malignancy in extramammary Paget's disease based on anatomic subtype. Journal of the American Academy of Dermatology 92(2):261-268, 2025. e-Pub 2025. PMID: 39401611.
7. Mustasam, A, Parza, K, Ionescu, F, Gullapalli, K, Paravathaneni, M, Kim, YC, Sandstrom, R, Assaad, MA, Grass, GD, Johnstone, PA, Eschrich, S, Safa, H, Chadha, J, Souza, GR, David, J, Semaan, A, Millward, NZ, Pettaway, CA, Giuliano, AR, Spiess, PE, Chahoud, J. The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma. JNCCN Journal of the National Comprehensive Cancer Network 23(2), 2025. e-Pub 2025. PMID: 39752880.
8. Cho, D, Li, Y, Basen-Engquist, KM, Acquati, C, Nguyen, N, Ma, HY, Pettaway, CA, McNeill, LH. Couple-based lifestyle intervention for minority prostate cancer survivors. Annals of Behavioral Medicine 59(1), 2025. e-Pub 2025. PMID: 39945428.
9. Gregg, JR, Newcomb, LF, Wu, R, Dennison, JB, Davis, JW, Pettaway, CA, Pisters, L, Ward, JF, Chapin, BF, Chery, LJ, Urkmez, A, Fang, A, Higgason, N, Troncoso, P, Daniel-MacDougall, CR, Logothetis, CJ, Thompson, TC, Hahn, AW, Liu, M, Zheng, Y, Lin, DW, Hanash, SM, Irajizad, E, Fahrmann, JF. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39522029.
10. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
11. Vreeburg, MT, Donswijk, ML, Albersen, M, Parnham, AS, Ayres, B, Protzel, C, Pettaway, CA, Spiess, PE, Brouwer, OR. New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective. European Journal of Nuclear Medicine and Molecular Imaging 51(10):2861-2868, 2024. e-Pub 2024. PMID: 38216778.
12. Sotelo R, Sayegh AS, Medina LG, Perez LC, La Riva A, Eppler MB, Gaona J, Tobias-Machado M, Spiess PE, Pettaway CA, Lima Pompeo AC, Lima Mattos PA, Wilson TG, Villoldo GM, Chung E, Samaniego A, Ornellas AA, Pinheiro V, Brazão ES, Subira-Rios D, Koifman L, Zequi SC, Pontillo Z HM, Rodrigues Calixto JR, Campos Silva R, Smithers BM, Garzon S, Haase O, Sommariva A, Fruscio R, Martins F, de Oliveira PS, Levi Sandri GB, Clementi M, Astigueta J, Metwally IH, Bharathan R, Jindal T, Nakamura Y, Abdel Mageed H, Jeevarajan S, Rodriguez Lay R, García-Perdomo HA, Rodríguez González O, Ghodoussipour S, Gill I, Cacciamani GE. Complications and adverse events in lymphadenectomy of the inguinal area: worldwide expert consensus. BJS Open 8(4), 2024. e-Pub 2024. PMID: 38987232.
13. Greco I, Fernandez-Pello S, Sakalis VI, Barreto L, Albersen M, Ayres B, Antunes Lopes T, Campi R, Crook J, García Perdomo HA, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Parnham AS, Pettaway CA, Protzel C, Rumble RB, Sachdeva A, Sanchez Martinez DF, Zapala L, Tagawa ST, Spiess PE, Brouwer OR. Systematic Review and Meta-analysis of Minimally Invasive Procedures for Surgical Inguinal Nodal Staging in Penile Carcinoma. Eur Urol Focus 10(4):567-580, 2024. e-Pub 2023. PMID: 38071107.
14. Rose KM, Pham R, Zacharias NM, Ionescu F, Paravathaneni M, Marchetti KA, Sanchez D, Mustasam A, Sandstrom R, Vikram R, Dhillon J, Rao P, Schneider A, Pagliaro L, Alifrangis C, Albersen M, Roussel E, Master VA, Nazha B, Hernandez C, Moses KA, Protzel C, Montgomery J, Angel M, Tobias-Machado M, Spiess PE, Pettaway CA, Chahoud J. Neoadjuvant Platinum-Based chemotherapy and lymphadenectomy for penile cancer: an international, Multi-Institutional, Real-World study. J Natl Cancer Inst 116(6):966-973, 2024. e-Pub 2024. PMID: 38366627.
15. Elst, L, Vreeburg, MT, de Vries, HM, Vandermaesen, K, Murphy, T, Churchill, J, Fallara, G, Sanchez, D, Falcone, M, García-Perdomo, HA, Pettaway, CA, Hakenberg, OW, Johnstone, PA, Spiess, PE, Muneer, A, Sangar, VK, Parnham, AS, Ayres, B, Watkin, NA, Brouwer, OR, Albersen, M. Corporal Skip Metastases in Penile Squamous Cell Carcinoma. European Urology Oncology 7(3):478-484, 2024. e-Pub 2024. PMID: 37813746.
16. Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, Frencher SK, George DJ, Kibel AS, King SA, Kittles R, Mahal BA, Pettaway CA, Rebbeck T, Rose B, Vince R, Winn RA, Yamoah K, Oh WK. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evid 3(5):EVIDoa2300289, 2024. e-Pub 2024. PMID: 38815168.
17. Gu J, Chery L, González GMN, Huff C, Strom S, Jones JA, Griffith DP, Canfield SE, Wang X, Huang X, Roberson P, Meng QH, Troncoso P, Ittmann M, Covinsky M, Scheurer M, Irizarry Ramirez M, Pettaway CA. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate 84(7):694-705, 2024. e-Pub 2024. PMID: 38477020.
18. Gregg, JR, Magill, RG, Fang, AM, Chapin, BF, Davis, JW, Adibi, M, Chery, LJ, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Ward, J, Hahn, AW, Daniel-MacDougall, CR, Bhaskaran, J, Zhu, K, Guerrero, M, Zhang, M, Troncoso, P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
19. Ozambela M, McCormick BZ, Rudzinski JK, Pieretti AC, González GMN, Meissner MA, Papadopoulos JN, Adibi M, Matin SF, Dahmen AS, Spiess PE, Pettaway CA. Robotic or open superficial inguinal lymph node dissection as staging procedures for clinically node negative high risk penile cancer. Urol Oncol 42(4):120.e1-120.e9, 2024. e-Pub 2024. PMID: 38388244.
20. Cho D, Gor B, Hwang H, Wang X, Hernandez M, Jones LA, Frost J, Roberson P, Pettaway CA. A Community-Based Prostate Cancer Screening and Education Program for Asian American Men in Medically Underserved Communities. Int J Environ Res Public Health 21(4), 2024. e-Pub 2024. PMID: 38673327.
21. Zacharias NM, Segarra L, Akagi K, Fowlkes NW, Chen H, Alaniz A, de la Cerda C, Pesquera P, Xi Y, Wang J, Chahoud J, Lu X, Rao P, Martinez-Ferrer M, Pettaway CA. Transcriptomic, Proteomic, and Genomic Mutational Fraction Differences Based on HPV Status Observed in Patient-Derived Xenograft Models of Penile Squamous Cell Carcinoma. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473423.
22. Sachdeva A, McGuinness L, Zapala L, Greco I, Garcia-Perdomo HA, Kailavasan M, Antunes-Lopes T, Ayres B, Barreto L, Campi R, Crook J, Johnstone P, Kumar V, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Protzel C, Bryan Rumble R, Sánchez Martínez DF, Spiess PE, Tagawa ST, van der Heijden MS, Parnham AS, Pettaway CA, Albersen M, Sangar VK, Brouwer OR, Sakalis VI. Management of Lymph Node-positive Penile Cancer: A Systematic Review. Eur Urol 85(3):257-273, 2024. e-Pub 2023. PMID: 37208237.
23. Ionescu F, Nguyen J, Segura CM, Paravathaneni M, Grass GD, Johnstone P, Zacharias NM, Pettaway CA, Lu X, Kim Y, Whiting J, Dhillon J, Eschrich SA, Chadha J, Gullapalli K, Roman Souza G, Miyagi H, Manley BJ, Spiess PE, Chahoud J. Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage. Cancers (Basel) 16(2), 2024. e-Pub 2024. PMID: 38275860.
24. Garraway, IP, Carlsson, SV, Nyame, YA, Vassey, J, Chilov, M, Fleming, MT, Frencher, SK, George, DJ, Kibel, AS, King, SA, Kittles, RA, Mahal, BA, Pettaway, CA, Rebbeck, TR, Rose, B, Vince, R, Winn, RA, Yamoah, K, Oh, WK. Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
25. Neubauer, R, Pettaway, CA, Spiess, PE, Jain, R, Chadha, J, Zhang, J, Chahoud, J, Roman Souza, G, Dhillon, J, Moscu, A, Janeway, R, Harris, DW, Lu, X, Jameel, G, Raymond, S, Oschmann, E, Kim, YC, Campbell, M, Schuckman, AK. A phase 2 study of the combination dostarlimab with niraparib in patients with penile carcinoma that has progressed following chemotherapy. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
26. Moussa, MJ, Chen, AH, Grana, AK, Gao, J, Shah, AY, Corn, P, Tannir, NM, Goswami, S, Wang, J, Araujo, JC, Kamat, A, Navai, N, Pettaway, CA, Adibi, M, Czerniak, BA, Guo, CC, Siefker-Radtke, AO, Campbell, M, Alhalabi, O. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
27. Brouwer OR, Rumble RB, Ayres B, Sánchez Martínez DF, Oliveira P, Spiess PE, Johnstone PAS, Crook J, Pettaway CA, Tagawa ST, Update Panel MOTEPC. Penile Cancer: EAU-ASCO Collaborative Guidelines Update Q and A. JCO Oncol Pract 20(1):33-37, 2024. e-Pub 2024. PMID: 37956391.
28. El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst 115(12):1605-1615, 2023. e-Pub 2023. PMID: 37563779.
29. May M, Lebentrau S, Watkin N, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Hakenberg OW, Ayres B, Spiess PE. [Initial presentation of the Pentafecta score as a quality instrument for outcome evaluation of primary surgical treatment in patients with penile cancer]. Aktuelle Urol 54(4):292-298, 2023. e-Pub 2023. PMID: 37339668.
30. Parza K, Mustasam A, Ionescu F, Paravathaneni M, Sandstrom R, Safa H, Grass GD, Johnstone PA, Eschrich SA, Chadha J, Zacharias N, Pettaway CA, Spiess PE, Chahoud J. The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma-A Systematic Review. Cancers (Basel) 15(14), 2023. e-Pub 2023. PMID: 37509374.
31. Prakash G, Arora A, Bandini M, Basile G, Pal M, Griffiths G, Cornes R, Zhu Y, Rodriguez A, Alberson M, Necchi A, Master V, Pettaway CA, Spiess PE. Variations in Penile Cancer Management: Results From the Global Society of Rare Genitourinary Tumors Survey. Clin Genitourin Cancer 21(3):376-382, 2023. e-Pub 2023. PMID: 37037737.
32. Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, Antunes-Lopes T, Barreto L, Campi R, Crook J, Fernández-Pello S, Greco I, van der Heijden MS, Johnstone PAS, Kailavasan M, Manzie K, Marcus JD, Necchi A, Oliveira P, Osborne J, Pagliaro LC, Garcia-Perdomo HA, Rumble RB, Sachdeva A, Sakalis VI, Zapala L, Sánchez Martínez DF, Spiess PE, Tagawa ST. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol 83(6):548-560, 2023. e-Pub 2023. PMID: 36906413.
33. May M, Lebentrau S, Ayres B, Albersen M, Protzel C, Chahoud J, Brouwer OR, Pettaway CA, Pagliaro LC, Necchi A, Watkin N, Hakenberg OW, Spiess PE. The Goal of Achieving High-Quality Surgical First-Line Therapy in Patients with Penile Cancer Is Important; However, Some Collective Efforts Are Still Required in Order to Reach It. Comment on Brassetti et al. Combined Reporting of Surgical Quality and Cancer Control after Surgical Treatment for Penile Tumors with Inguinal Lymph Node Dissection: The Tetrafecta Achievement. Curr. Oncol. 2023, 30, 1882-1892. Curr Oncol 30(4):4269-4274, 2023. e-Pub 2023. PMID: 37185438.
34. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
35. Chahoud J, Zacharias NM, Pham R, Qiao W, Guo M, Lu X, Alaniz A, Segarra L, Martinez-Ferrer M, Gleber-Netto FO, Pickering CR, Rao P, Pettaway CA. Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up. Cancers (Basel) 14(24), 2022. e-Pub 2022. PMID: 36551510.
36. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int 130(5):604-610, 2022. e-Pub 2021. PMID: 34773684.
37. Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
38. Sakalis VI, Campi R, Barreto L, Perdomo HG, Greco I, Zapala L, Kailavasan M, Antunes-Lopes T, Marcus JD, Manzie K, Osborne J, Ayres B, Moonen LMF, Necchi A, Crook J, Oliveira P, Pagliaro LC, Protzel C, Parnham AS, Albersen M, Pettaway CA, Spiess PE, Tagawa ST, Rumble RB, Brouwer OR. What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. Eur Urol Open Sci 40:58-94, 2022. e-Pub 2022. PMID: 35540709.
39. Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncol 8(4):618-628, 2022. e-Pub 2022. PMID: 35050310.
40. Crook, J, Black, P, Spiess, PE, Pettaway, CA. The first International Penile Advanced Cancer Trial (InPACT) opens in Canada! Why additional centers are needed. Canadian Urological Association Journal 16(2):70-71, 2022. e-Pub 2022. PMID: 35133267.
41. Mustafa, MO, Ward, JF, Davis, JW, Pettaway, CA, Pisters, LL. Transperineal saturation prostate biopsy in treated and untreated patients. Palestinian Medical and Pharmaceutical Journal 5(2):117-124, 2022. e-Pub 2022.
42. Shapiro DD, Davis JW, Williams WH, Chapin BF, Ward JF, Pettaway CA, Gregg JR. Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass 3(1):68-74, 2022. e-Pub 2022. PMID: 35475154.
43. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
44. Xu Y, Tsai CW, Chang WS, Han Y, Huang M, Pettaway CA, Bau DT, Gu J. Epigenome-Wide Association Study of Prostate Cancer in African Americans Identifies DNA Methylation Biomarkers for Aggressive Disease. Biomolecules 11(12), 2021. e-Pub 2021. PMID: 34944472.
45. Dahlstrom KR, Anderson KS, Guo M, Kwon MC, Messick CA, Pettaway CA, Asomaning N, Hopper M, Price A, Xu L, Day AT, Gillenwater AM, Sturgis EM. Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncol 120:105397. e-Pub 2021. PMID: 34182223.
46. Graff M, Justice AE, Young KL, Marouli E, Zhang X, Fine RS, Lim E, Buchanan V, Rand K, Feitosa MF, Wojczynski MK, Yanek LR, Shao Y, Rohde R, Adeyemo AA, Aldrich MC, Allison MA, Ambrosone CB, Ambs S, Amos C, Arnett DK, Atwood L, Bandera EV, Bartz T, Becker DM, Berndt SI, Bernstein L, Bielak LF, Blot WJ, Bottinger EP, Bowden DW, Bradfield JP, Brody JA, Broeckel U, Burke G, Cade BE, Cai Q, Caporaso N, Carlson C, Carpten J, Casey G, Chanock SJ, Chen G, Chen M, Chen YI, Chen WM, Chesi A, Chiang CWK, Chu L, Coetzee GA, Conti DV, Cooper RS, Cushman M, Demerath E, Deming SL, Dimitrov L, Ding J, Diver WR, Duan Q, Evans MK, Falusi AG, Faul JD, Fornage M, Fox C, Freedman BI, Garcia M, Gillanders EM, Goodman P, Gottesman O, Grant SFA, Guo X, Hakonarson H, Haritunians T, Harris TB, Harris CC, Henderson BE, Hennis A, Hernandez DG, Hirschhorn JN, McNeill LH, Howard TD, Howard B, Hsing AW, Hsu YH, Hu JJ, Huff CD, Huo D, Ingles SA, Irvin MR, John EM, Johnson KC, Jordan JM, Kabagambe EK, Kang SJ, Kardia SL, Keating BJ, Kittles RA, Klein EA, Kolb S, Kolonel LN, Kooperberg C, Kuller L, Kutlar A, Lange L, Langefeld CD, Le Marchand L, Leonard H, Lettre G, Levin AM, Li Y, Li J, Liu Y, Liu Y, Liu S, Lohman K, Lotay V, Lu Y, Maixner W, Manson JE, McKnight B, Meng Y, Monda KL, Monroe K, Moore JH, Mosley TH, Mudgal P, Murphy AB, Nadukuru R, Nalls MA, Nathanson KL, Nayak U, N'Diaye A, Nemesure B, Neslund-Dudas C, Neuhouser ML, Nyante S, Ochs-Balcom H, Ogundiran TO, Ogunniyi A, Ojengbede O, Okut H, Olopade OI, Olshan A, Padhukasahasram B, Palmer J, Palmer CD, Palmer ND, Papanicolaou G, Patel SR, Pettaway CA, Peyser PA, Press MF, Rao DC, Rasmussen-Torvik LJ, Redline S, Reiner AP, Rhie SK, Rodriguez-Gil JL, Rotimi CN, Rotter JI, Ruiz-Narvaez EA, Rybicki BA, Salako B, Sale MM, Sanderson M, Schadt E, Schreiner PJ, Schurmann C, Schwartz AG, Shriner DA, Signorello LB, Singleton AB, Siscovick DS, Smith JA, Smith S, Speliotes E, Spitz M, Stanford JL, Stevens VL, Stram A, Strom SS, Sucheston L, Sun YV. Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. Am J Hum Genet 108(4):564-582, 2021. e-Pub 2021. PMID: 33713608.
47. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. e-Pub 2021. PMID: 33770291.
48. Marilin N, Master VA, Pettaway CA, Spiess PE. Current practice patterns of society of urologic oncology members in performing inguinal lymph node staging/therapy for penile cancer: A survey study. Urol Oncol. e-Pub 2021. PMID: 33775532.
49. Chahoud J, Gleber-Netto FO, McCormick BZ, Rao P, Lu X, Guo M, Morgan MB, Chu RA, Martinez-Ferrer M, Eterovic AK, Pickering CR, Pettaway CA. Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. e-Pub 2021. PMID: 33441293.
50. Cho D, Milbury K, Liao Y, Pettaway CA, Gregg JR, Li Y, McNeill LH. Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners. PLoS One 16(8):e0255614, 2021. e-Pub 2021. PMID: 34370761.
51. Carmack CL, Parker NH, Demark-Wahnefried W, Shely L, Baum G, Yuan Y, Giordano SH, Rodriguez-Bigas M, Pettaway C, Basen-Engquist K. Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Randomized Controlled Trial. Nutrients 13(12):4460, 2021. e-Pub 2021.
52. Kokorovic A, Duplisea J, Qiao W, McCormick B, Adibi M, Papadopoulos J, Ramirez G, Rao P, Tamboli P, Pettaway C. Clinical Testis Cancer: Oncologic outcomes and subsequent treatment following organ sparing surgery for penile carcinoma: The University of Texas M.D. Anderson Cancer Center Experience. Urol Oncol 39(5):e19-302-e27, 2021. e-Pub 2021.
53. Umbreit EC, McIntosh AG, Suk-Ouichai C, Segarra LA, Holland LC, Fellman BM, Williams SB, Thomas AZ, Tu SM, Pettaway CA, Pisters LL, Ward JF, Wood CG, Karam JA. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer 126(22):4878-4885, 2020. e-Pub 2020. PMID: 32940929.
54. Shen X, Pettaway CA, Chen RC. Active Surveillance for Black Men With Low-Risk Prostate Cancer. JAMA 324(17):1733-1734, 2020. e-Pub 2020. PMID: 33141193.
55. Tsai CW, Chang WS, Xu J, Xu Y, Huang M, Pettaway C, Bau DT, Gu J. Leukocyte telomere length is associated with aggressive prostate cancer in localized African American prostate cancer patients. Carcinogenesis 41(9):1213-1218, 2020. e-Pub 2020. PMID: 32614411.
56. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol 38(24):2798-2811, 2020. e-Pub 2020. PMID: 32516092.
57. Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P, Guo M, Manyam G, Zhang L, Xiang Y, Han L, Shang X, Deng P, Luo Y, Lu X, Feng S, Ferrer MM, Alan Wang Y, DePinho RA, Pettaway CA, Lu X. Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun 11(1):2124, 2020. e-Pub 2020. PMID: 32358507.
58. Cho D, Basen-Engquist K, Acquati C, Ma H, Pettaway C, Yisheng L, Diep CS, McNeill LM. Study Protocol: A lifestyle intervention for African American and Hispanic prostate cancer survivors on active surveillance and their partners. Pilot and Feasibility Studies 111, 2020. e-Pub 2020. PMID: 32782817.
59. Cho D, Basen-Engquist K, Acquati C, Pettaway C, Ma H, Markofski M, Li Y, Canfield SE, Gregg J, McNeill LH. Cultural Adaptation of Evidence-Based Lifestyle Interventions for African American Men With Prostate Cancer: A Dyadic Approach. Am J Mens Health 14(6), 2020. e-Pub 2020. PMID: 3148111.
60. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. e-Pub 2019. PMID: 31742674.
61. Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers (Basel) 11(6), 2019. e-Pub 2019. PMID: 31146499.
62. Canter DJ, Nicholson S, Watkin N, Hall E, Pettaway C, Committee IE. The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status. Eur Urol Focus, 2019. e-Pub 2019.
63. Lairson DR, Wu CF, Chan W, Fu S, Hoffman KE, Pettaway CA. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urol Oncol 37(4):294.e17-294.e25, 2019. e-Pub 2019. PMID: 30660492.
64. Xu J, Tsai CW, Chang WS, Han Y, Bau DT, Pettaway CA, Gu J. Methylation of global DNA repeat LINE-1 and subtelomeric DNA repeats D4Z4 in leukocytes is associated with biochemical recurrence in African American prostate cancer patients. Carcinogenesis. e-Pub 2019. PMID: 30874286.
65. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol 74(2):140-143, 2018. e-Pub 2018. PMID: 29656854.
66. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. e-Pub 2018. PMID: 29988098.
67. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol:JCO2017741173. e-Pub 2017. PMID: 29236593.
68. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol. e-Pub 2017. PMID: 28964658.
69. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. e-Pub 2017. PMID: 28941030.
70. Zhang M, Adeniran AJ, Vikram R, Tamboli P, Pettaway C, Bondaruk J, Liu J, Baggerly K, Czerniak B. Carcinoma of the Urethra. Hum Pathol. e-Pub 2017. PMID: 28827100.
71. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. e-Pub 2017. PMID: 28710901.
72. Irizarry-Ramírez M, Kittles RA, Wang X, Salgado-Montilla J, Nogueras-González GM, Sánchez-Ortiz R, Guerrios L, Rivera K, Shah E, Prokhorova I, Roberson P, Troncoso P, Pettaway CA. Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. Prostate 77(10):1118-1127, 2017. e-Pub 2017. PMID: 28543179.
73. Gilani S, Guo CC, Li-Ning EM, Pettaway C, Troncoso P. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol 64:186-190, 2017. e-Pub 2017. PMID: 28159676.
74. Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123(9):1536-1544, 2017. e-Pub 2017. PMID: 28055108.
75. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. e-Pub 2017. PMID: 28346412.
76. Zhang M, Pettaway C, Vikram R, Tamboli P. Adenoid cystic carcinoma of the urethra/Cowper's gland with concurrent high-grade prostatic adenocarcinoma: a detailed clinicopathologic case report and review of the literature. Hum Pathol 58:138-144, 2016. e-Pub 2016. PMID: 27554206.
77. Reddy JP, Pettaway CA, Levy LB, Pagliaro LC, Tamboli P, Rao P, Jayaratna I, Hoffman KE. Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. BJU Int. e-Pub 2016. PMID: 27753187.
78. Gökce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D, Canfield SE, Pettaway CA. Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer. e-Pub 2016. PMID: 27727462.
79. Sharma P, Zargar-Shoshtari K, Pettaway CA, Schabath MB, Giuliano AR, Spiess PE. Disparities in Penile Cancer. Cancer Control 23(4):409-414, 2016. e-Pub 2016. PMID: 27842330.
80. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson I, Carroll P, Eastham J, Gomella L, Klein E. An Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. e-Pub 2016. PMID: 27450937.
81. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favorable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2016. PMID: 26059275.
82. Han Y, Rand KA, Hazelett DJ, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Schumacher FR, Berndt SI, Wang Z, Xu J, Rohland N, Reich D, Tandon A, Pasaniuc B, Allen A, Quinque D, Mallick S, Notani D, Rosenfeld MG, Jayani RS, Kolb S, Gapstur SM, Stevens VL, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Witte JS, Casey G, Lubwama A, Pooler LC, Sheng X, Coetzee GA, Cook MB, Chanock SJ, Stram DO, Watya S, Blot WJ, Conti DV, Henderson BE, Haiman CA. Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. J Natl Cancer Inst 108(7), 2016. e-Pub 2016. PMID: 26823525.
83. Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward JF, Davis JW, Pisters LL. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol 23(3):8271-7, 2016. e-Pub 2016. PMID: 27347619.
84. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine 7:85-93, 2016. e-Pub 2016. PMID: 27322462.
85. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer 14(2):130-8, 2016. e-Pub 2016. PMID: 26558524.
86. Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic Factors Influencing Survival from Regionally Advanced Squamous Cell Carcinoma of the Penis After Preoperative Chemotherapy. BJU Int 117(1):118-25, 2016. e-Pub 2016. PMID: 25294319.
87. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674, 2016. e-Pub 2016. PMID: 27241286.
88. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A, consortium P, Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun 7:10979, 2016. e-Pub 2016. PMID: 27052111.
89. Han Y, Hazelett DJ, Wiklund F, Schumacher FR, Stram DO, Berndt SI, Wang Z, Rand KA, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Xu J, Travis RC, Key TJ, Siddiq A, Canzian F, Takahashi A, Kubo M, Stanford JL, Kolb S, Gapstur SM, Diver WR, Stevens VL, Strom SS, Pettaway CA, Al Olama AA, Kote-Jarai Z, Eeles RA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Isaacs WB, Chen C, Lindstrom S, Le Marchand L, Giovannucci EL, Pomerantz M, Long H, Li F, Ma J, Stampfer M, John EM, Ingles SA, Kittles RA, Murphy AB, Blot WJ, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske MC, Wu SY, Hennis AJ, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Witte JS, Casey G, Riboli E, Li Q, Freedman ML, Hunter DJ, Gronberg H, Cook MB, Nakagawa H, Kraft P, Chanock SJ, Easton DF, Henderson BE, Coetzee GA, Conti DV, Haiman CA. Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet 24(19):5603-18, 2015. e-Pub 2015. PMID: 26162851.
90. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 18(3):276-80, 2015. e-Pub 2015. PMID: 26171883.
91. Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A, Aronson W, Clark W, Simmons G, Heber D. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis 18(3):242-8, 2015. e-Pub 2015. PMID: 26169045.
92. Ashorobi OS, Frost J, Wang X, Roberson P, Lin E, Volk RJ, Lopez DS, Jones LA, Pettaway CA. Prostate Cancer Education, Detection, and Follow-Up in a Community-Based Multiethnic Cohort of Medically Underserved Men. Am J Mens Health. e-Pub 2015. PMID: 25986045.
93. Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology 85(5):1104-10, 2015. e-Pub 2015. PMID: 25819619.
94. Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, Goodman PJ, Berndt SI, Carpten J, Casey G, Chu L, Conti DV, Rand KA, Diver WR, Hennis AJ, John EM, Kibel AS, Klein EA, Kolb S, Le Marchand L, Leske MC, Murphy AB, Neslund-Dudas C, Park JY, Pettaway C, Rebbeck TR, Gapstur SM, Zheng SL, Wu SY, Witte JS, Xu J, Isaacs W, Ingles SA, Hsing A, Consortium P, Consortium EG, Easton DF, Eeles RA, Schumacher FR, Chanock S, Nemesure B, Blot WJ, Stram DO, Henderson BE, Haiman CA. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136(5):1210-7, 2015. e-Pub 2015. PMID: 25044450.
95. Mustafa M, Pettaway CA, Davis JW, Pisters L. Robotic or open radical prostatectomy after previous open surgery in the pelvic region. Korean J Urol 56(2):131-7, 2015. e-Pub 2015. PMID: 25685300.
96. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Breast, Cohort Consortium PC, Consortium P, Consortium C, Consortium G, Cook MB, Nakagawa H, Wiklund F. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46(10):1103-9, 2014. e-Pub 2014. PMID: 25217961.
97. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 2014. e-Pub 2014. PMID: 24994920.
98. Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal Growth Factor Receptor-Targeted Therapy in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis. BJU Int 113(6):871-7, 2014. e-Pub 2014. PMID: 24053151.
99. McFall SL, Mullen PD, Byrd TL, Cantor SB, Le YC, Torres-Vigil I, Pettaway C, Volk RJ. Treatment decisions for localized prostate cancer: a concept mapping approach. Health Expect. e-Pub 2014. PMID: 24506829.
100. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol 4(6):e239-46, 2014. e-Pub 2014. PMID: 25407875.
101. Gilts CD, Parker PA, Pettaway CA, Cohen L. Psychosocial moderators of presurgical stress management for men undergoing radical prostatectomy. Health Psychol 32(12):1218-26, 2013. e-Pub 2013. PMID: 23088178.
102. Ratcliff CG, Cohen L, Pettaway CA, Parker PA. Treatment regret and quality of life following radical prostatectomy. Support Care Cancer 21(12):3337-43, 2013. e-Pub 2013. PMID: 23907238.
103. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 31(7):1171-7, 2013. e-Pub 2013. PMID: 22534087.
104. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 111(7):1068-74, 2013. e-Pub 2013. PMID: 23551693.
105. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 2013. e-Pub 2013. PMID: 22753310.
106. Liu CT, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, Wojczynski MK, Ellis JC, Vitolins MZ, Liu S, Papanicolaou GJ, Irvin MR, Xue L, Griffin PJ, Nalls MA, Adeyemo A, Liu J, Li G, Ruiz-Narvaez EA, Chen WM, Chen F, Henderson BE, Millikan RC, Ambrosone CB, Strom SS, Guo X, Andrews JS, Sun YV, Mosley TH, Yanek LR, Shriner D, Haritunians T, Rotter JI, Speliotes EK, Smith M, Rosenberg L, Mychaleckyj J, Nayak U, Spruill I, Garvey WT, Pettaway C, Nyante S, Bandera EV, Britton AF, Zonderman AB, Rasmussen-Torvik LJ, Chen YD, Ding J, Lohman K, Kritchevsky SB, Zhao W, Peyser PA, Kardia SL, Kabagambe E, Broeckel U, Chen G, Zhou J, Wassertheil-Smoller S, Neuhouser ML, Rampersaud E, Psaty B, Kooperberg C, Manson JE, Kuller LH, Ochs-Balcom HM, Johnson KC, Sucheston L, Ordovas JM, Palmer JR, Haiman CA, McKnight B, Howard BV, Becker DM, Bielak LF, Liu Y, Allison MA, Grant SF, Burke GL, Patel SR, Schreiner PJ, Borecki IB, Evans MK, Taylor H, Sale MM, Howard V, Carlson CS, Rotimi CN, Cushman M, Harris TB, Reiner AP, Cupples LA, North KE, Fox CS. Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet 9(8):e1003681, 2013. e-Pub 2013. PMID: 23966867.
107. Soto-Salgado M, Suárez E, Torres-Cintrón M, Pettaway CA, Colón V, Ortiz AP. Prostate cancer incidence and mortality among Puerto Ricans: an updated analysis comparing men in Puerto Rico with US racial/ethnic groups. P R Health Sci J 31(3):107-13, 2012. e-Pub 2012. PMID: 23038882.
108. Pisters PW, Pettaway CA, Liu P, Matin SF, Ward JF, Leibovici D. Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective?. J Surg Oncol 106(1):62-5, 2012. e-Pub 2012. PMID: 22259198.
109. Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 109(8):1162-9, 2012. e-Pub 2012. PMID: 21699645.
110. Colón-López V, Ortiz AP, Soto-Salgado M, Torres-Cintrón M, Pettaway CA, Puras-Báez A, Martínez-Ferrer M, Suárez E. Penile cancer disparities in Puerto Rican men as compared to the United States population. Int Braz J Urol 38(6):728-38, 2012. e-Pub 2012. PMID: 23302411.
111. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15(2):367-75, 2012. e-Pub 2012. PMID: 22433769.
112. Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU Int 108(11):1743-9, 2011. e-Pub 2011. PMID: 21711431.
113. N'Diaye A, Chen GK, Palmer CD, Ge B, Tayo B, Mathias RA, Ding J, Nalls MA, Adeyemo A, Adoue V, Ambrosone CB, Atwood L, Bandera EV, Becker LC, Berndt SI, Bernstein L, Blot WJ, Boerwinkle E, Britton A, Casey G, Chanock SJ, Demerath E, Deming SL, Diver WR, Fox C, Harris TB, Hernandez DG, Hu JJ, Ingles SA, John EM, Johnson C, Keating B, Kittles RA, Kolonel LN, Kritchevsky SB, Le Marchand L, Lohman K, Liu J, Millikan RC, Murphy A, Musani S, Neslund-Dudas C, North KE, Nyante S, Ogunniyi A, Ostrander EA, Papanicolaou G, Patel S, Pettaway CA, Press MF, Redline S, Rodriguez-Gil JL, Rotimi C, Rybicki BA, Salako B, Schreiner PJ, Signorello LB, Singleton AB, Stanford JL, Stram AH, Stram DO, Strom SS, Suktitipat B, Thun MJ, Witte JS, Yanek LR, Ziegler RG, Zheng W, Zhu X, Zmuda JM, Zonderman AB, Evans MK, Liu Y, Becker DM, Cooper RS, Pastinen T, Henderson BE, Hirschhorn JN, Lettre G, Haiman CA. Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet 7(10):e1002298, 2011. e-Pub 2011. PMID: 21998595.
114. Pettaway CA, Lamerato LE, Eaddy MT, Edwards JK, Hogue SL, Crane MM. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int 108(8):1302-8, 2011. e-Pub 2011. PMID: 21371244.
115. Sterba KR, Swartz RJ, Basen-Engquist K, Black PC, Pettaway CA. Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial. Support Care Cancer 19(8):1117-24, 2011. e-Pub 2011. PMID: 20499107.
116. Hegarty PK, Suh J, Fisher MB, Taylor J, Nguyen TH, Ivan D, Prieto VG, Pagliaro LC, Pettaway CA. Penoscrotal extramammary Paget's disease: the University of Texas M. D. Anderson Cancer Center contemporary experience. J Urol 186(1):97-102, 2011. e-Pub 2011. PMID: 21571343.
117. del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD. Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments. J Urol 185(6):2137-42, 2011. e-Pub 2011. PMID: 21496842.
118. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574-81, 2011. e-Pub 2011. PMID: 21606419.
119. Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, Pisters L, Miles B, Wei Q, Wiltz L, Patel T, Radvanyi L. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med 73(3):218-25, 2011. e-Pub 2011. PMID: 21257977.
120. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS, Group RS. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 185(1):126-31, 2011. e-Pub 2011. PMID: 21074214.
121. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28(24):3851-7, 2010. e-Pub 2010. PMID: 20625118.
122. Song R, Harris LD, Pettaway CA. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway. Prostate 70(6):571-83, 2010. e-Pub 2010. PMID: 19938012.
123. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192-202, 2010. e-Pub 2010. PMID: 20357281.
124. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10:599, 2010. e-Pub 2010. PMID: 21044312.
125. Zafirakis H, De EJ, Pisters LL, Pettaway C, Westney OL. Long-term outcomes and patient satisfaction of continent catheterizable limb and augmentation cystoplasty simultaneous with salvage prostatectomy. Neurourol Urodyn 29 Suppl 1:S51-6, 2010. e-Pub 2010. PMID: 20419802.
126. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. Eur Urol. e-Pub 2009. PMID: 19853370.
127. Davis JW, Kamat A, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized?. BJU Int. e-Pub 2009. PMID: 19874300.
128. Parker PA, Pettaway CA, Babaian RJ, Pisters LL, Miles B, Fortier A, Wei Q, Carr DD, Cohen L. The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 27(19):3169-76, 2009. e-Pub 2009. PMID: 19349551.
129. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 55(5):1135-43, 2009. e-Pub 2009. PMID: 18783876.
130. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. e-Pub 2009. PMID: 19244175.
131. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
132. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 181(1):81-7; discussion 87, 2009. e-Pub 2009. PMID: 19012911.
133. Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol 182(6):2721-7, 2009. e-Pub 2009. PMID: 19837433.
134. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA. Association of HPC2/ELAC2 and RNASEL Non-Synonymous Variants With Prostate Cancer Risk in African American Familial and Sporadic Cases. Prostate 68(16):1790-1797, 2008. e-Pub 2008. PMID: 18767027.
135. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant Transformation of Testicular Teratoma: A chemoresistant Phenotype. Urol Oncol 26(6):595-9, 2008. e-Pub 2008. PMID: 18367105.
136. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate 68(13):1467-76, 2008. e-Pub 2008. PMID: 18618693.
137. Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to e-cadherin expression level: prognostic significance of mRNA and protein expression among African American prostate cancer patients. The Prostate 68(13):1467-1476, 2008. e-Pub 2008.
138. Strom SS, Yamamura Y, Forman MR, Pettaway CA, Barrera SL, DiGiovanni J. Saturated Fat Intake Predicts Biochemical Failure after Prostatectomy. Int J Cancer 122(11):2581-2585, 2008. e-Pub 2008. PMID: 18324626.
139. Strom SS, Yamamura Y, Flores-Sandoval FN, Pettaway CA, Lopez DS. Prostate Cancer in Mexican-Americans: Identification of Risk Factors. Prostate 68(5):563-570, 2008. e-Pub 2008. PMID: 18247399.
140. Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS. Clinical model of cost of bladder cancer in the elderly. Urology 71(3):519-25, 2008. e-Pub 2008. PMID: 18342201.
141. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and Age Differences in Blood Utilization and Length of Stay in Radical Cystectomy: A Population-based Study. Int Urol Nephrol 40(4):893-9, 2008. e-Pub 2008. PMID: 18317944.
142. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 110(8):1729-1737, 2007. e-Pub 2007. PMID: 17786954.
143. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB. Organ Preservation for Muscle-invasive Bladder Cancer by Transurethral Resection. Urology 70(3):473-476, 2007. e-Pub 2007. PMID: 17905099.
144. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Urology 70(2):252-256, 2007. e-Pub 2007. PMID: 17826484.
145. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 100(1):63-9, 2007. e-Pub 2007. PMID: 17552954.
146. Weinrich S, Vijayakumar S, Powell IJ, Priest J, Hamner CA, McCloud L, Pettaway C. Knowledge of Hereditary Prostate Cancer among HIgh-Risk African American Men. Oncol Nurs Forum 34(4)(4):854-60, 2007. e-Pub 2007. PMID: 17723986.
147. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient-reported continence outcomes at 32 months. J Urol 177(6)(6):2200-04, 2007. e-Pub 2007. PMID: 17509319.
148. Spiess PE, Izawa JI, Bassett R, Kedar D, Busby JE, Wong F, Eddings T, Tamboli P, Pettaway CA. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 177(6):2157-61, 2007. e-Pub 2007. PMID: 17509308.
149. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 177(4)(4):1335-38, 2007. e-Pub 2007. PMID: 17382727.
150. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4)(4):1224-1231, 2007. e-Pub 2007. PMID: 17317833.
151. Carmack Taylor CL, de Moor C, Basen-Engquist K, Smith MA, Dunn AL, Badr H, Pettaway C, Gritz ER. Moderator analyses of participants in the Active for Life after Cancer trial: implications for physical activity group intervention studies. Ann Behav Med 33(1)(1):99-104, 2007. e-Pub 2007. PMID: 17291175.
152. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate Cancer Progression in the Presence of Undetectable or Low Serum Prostate-Specific Antigen Level. Cancer 109(2)(2):198-204, 2007. e-Pub 2007. PMID: 17171704.
153. Baffoe-Bonnie AB, Kittles RA, Gillanders E, Ou L, George A, Robbins C, Ahaghotu C, Bennett J, Boykin W, Hoke G, Mason T, Pettaway C, Vijayakumar S, Weinrich S, Jones MP, Gildea D, Riedesel E, Albertus J, Moses T, Lockwood E, Klaric M, Faruque M, Royal C, Trent JM, Berg K, Collins FS, Furbert-Harris PM, Bailey-Wilson JE, Dunston GM, Powell I, Carpten JD. Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer Study (AAHPC). Prostate 67(1)(1):22-31, 2007. e-Pub 2007. PMID: 17031815.
154. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Pettaway CA. Randomized prospective trial evaluating testosterone, hemoglobin kinetics, and quality of life during and after 12 months of post-prostatectomy androgen deprivation. Results from the Postoperative Adjuvant Androgen Deprivation (PAAD) Trial. BJU 100(1):63-69, 2007. e-Pub 2007.
155. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 98(6):1176-80, 2006. e-Pub 2006. PMID: 17125474.
156. Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15(10):847-62, 2006. e-Pub 2006. PMID: 16447306.
157. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 2006. e-Pub 2006. PMID: 16952661.
158. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107(1):75-82, 2006. e-Pub 2006. PMID: 16736511.
159. Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L. Comparative outcomes of bladder cancer. Obstet Gynecol 108(1):169-75, 2006. e-Pub 2006. PMID: 16816072.
160. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43(6)(6):507-511, 2006. e-Pub 2006. PMID: 16155194.
161. Weinrich S, Weinrich M, Pettaway CA, Vijayakumar S, Powell IJ, Bennett JK, Ahaghotu CA, Hoke G, Mason T, Boykin WH, Priest J, Roberson-Smith, Frost J, Meegan C, Johnson E, Faison-Smith L, Atkinson C, Robertson T, Smith S, Mejia R, Royal C, Mensah E, Kittles R, Trent J, Carpten J, Berg K, Bailey-Wilson J, Baffoe-Bonnie A, Collins F, Dunston G. Prostate Cancer Screening in High Risk Men. Cancer 106(4):796-803, 2006. e-Pub 2006.
162. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 2005. e-Pub 2005. PMID: 16280761.
163. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889-94, 2005. e-Pub 2005. PMID: 16203779.
164. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer 104(5):975-84, 2005. e-Pub 2005. PMID: 16044400.
165. Eltin LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EBC, Saldin K, Dinney CPN. Correlation between annual volume of cystectomy, professional staffing, and outcomes. Cancer 104(5):975-84, 2005. e-Pub 2005.
166. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, 2005. e-Pub 2005. PMID: 16030104.
167. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11(12):4512-20, 2005. e-Pub 2005. PMID: 15958637.
168. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64(1):40-9, 2005. e-Pub 2005. PMID: 15651067.
169. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 173(6):1958-65, 2005. e-Pub 2005. PMID: 15879790.
170. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1):101-4, 2005. e-Pub 2005. PMID: 15389800.
171. Wyatt RB, Sánchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 2004. e-Pub 2004. PMID: 15622688.
172. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 2004. e-Pub 2004. PMID: 15264247.
173. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7):939-944, 2004. e-Pub 2004. PMID: 15253325.
174. Nakamori M, Fu X, Pettaway CA, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60(1):53-60, 2004. e-Pub 2004. PMID: 15129429.
175. Carmack Taylor CL, Smith MA, de Moor C, Dunn AL, Pettaway C, Sellin R, Charnsangavej C, Hansen MC, Gritz ER. Quality of life intervention for prostate cancer patients: design and baseline characteristics of the active for life after cancer trial. Control Clin Trials 25(3):265-285, 2004. e-Pub 2004. PMID: 15157729.
176. Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59(2):167-76, 2004. e-Pub 2004. PMID: 15042617.
177. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, 2004. e-Pub 2004. PMID: 15076299.
178. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 2004. e-Pub 2004. PMID: 15102659.
179. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2 alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 64(2):631-638, 2004. e-Pub 2004. PMID: 14744778.
180. Ahaghotu C, Baffoe-Bonnie A, Kittles R, Pettaway C, Powell I, Royal C, Wang H, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F. Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis 7(2):165-9, 2004. e-Pub 2004. PMID: 15175665.
181. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, 2003. e-Pub 2003. PMID: 14532795.
182. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, 2003. e-Pub 2003. PMID: 14532792.
183. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2(9):835-843, 2003. e-Pub 2003. PMID: 14555702.
184. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 9(6):2185-94, 2003. e-Pub 2003. PMID: 12796385.
185. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169(6):2113-7, 2003. e-Pub 2003. PMID: 12771730.
186. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-24, 2002. e-Pub 2002. PMID: 12171905.
187. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 2002. e-Pub 2002. PMID: 12173328.
188. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8(5):1253-1265, 2002. e-Pub 2002. PMID: 12006546.
189. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol 167(4):1638-42, 2002. e-Pub 2002. PMID: 11912379.
190. Weinrich S, Royal C, Pettaway CA, Dunston G, Faison-Smith L, Priest JH, Roberson-Smith P, Frost J, Jenkins J, Brooks KA, Powell I. Interest in genetic prostate cancer susceptibility testing among african American men. Cancer Nurs 25(1):28-34, 2002. e-Pub 2002. PMID: 11838717.
191. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F. African-American Heredity Prostate Cancer Study: A Model for Genetic Research. J Natl Med Assoc 93(4):25S-28S, 2001. e-Pub 2001. PMID: 11798061.
192. Giesler EJ, Gee JR, Reece GP, Pettaway CA, Pollock RE, Pisters LL. Cutaneous metastases of penile squamous cell carcinoma following en bloc resection of inguinal recurrence with immediate pedicle flap reconstruction. J Urol 166(4):1384-5, 2001. e-Pub 2001. PMID: 11547082.
193. Kuniyasu H, Yasui W, Pettaway CA, Yano S, Oue N, Tahara E, Fidler IJ. Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate 49(1):19-29, 2001. e-Pub 2001. PMID: 11550207.
194. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20(31):4188-97, 2001. e-Pub 2001. PMID: 11464285.
195. Chu LW, Pettaway CA, Liang JC. Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization. Cancer Genet Cytogenet 127(2):161-7, 2001. e-Pub 2001. PMID: 11425457.
196. Slaton JW, Morgenstern N, Levy DA, Santos MW, Tamboli P, Ro JY, Ayala AG, Pettaway CA. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol 165(4):1138-42, 2001. e-Pub 2001. PMID: 11257655.
197. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F. African-American Heredity Prostate Cancer Study: A Model for Genetic Research. J Natl Med Assoc 93(4):120-3, 2001. e-Pub 2001. PMID: 12653398.
198. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol 10(8 Suppl):S68-77, 2000. e-Pub 2000. PMID: 11189095.
199. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6(6):2295-308, 2000. e-Pub 2000. PMID: 10873080.
200. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6(5):2104-19, 2000. e-Pub 2000. PMID: 10815938.
201. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-7, 2000. e-Pub 2000. PMID: 10694556.
202. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoka G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghoto C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F. Recruitment experiences in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Annals of Epidemiology 10(8):S68 –77, 2000. e-Pub 2000.
203. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(S3):S27, 1999. e-Pub 1999. PMID: 12496806.
204. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5(4):783-9, 1999. e-Pub 1999. PMID: 10213213.
205. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, Fidler IJ. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59(4):872-879, 1999. e-Pub 1999. PMID: 10029078.
206. Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol 161(2):509-14, 1999. e-Pub 1999. PMID: 9915437.
207. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 160(5):1770-4, 1998. e-Pub 1998. PMID: 9783949.
208. Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 42(3):517-23, 1998. e-Pub 1998. PMID: 9806509.
209. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol 160(2):437-42, 1998. e-Pub 1998. PMID: 9679893.
210. Hall MC, Sanders JS, Vuitch F, Ramirez E, Pettaway CA. Deoxyribonucleic acid flow cytometry and traditional pathologic variables in invasive penile carcinoma: assessment of prognostic significance. Urology 52(1):111-6, 1998. e-Pub 1998. PMID: 9671880.
211. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 159(3):792-5, 1998. e-Pub 1998. PMID: 9474150.
212. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol 157(6):2120-3, 1997. e-Pub 1997. PMID: 9146596.
213. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150(5):1571-82, 1997. e-Pub 1997. PMID: 9137084.
214. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157(3):921-5, 1997. e-Pub 1997. PMID: 9072600.
215. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56(24):5594-9, 1996. e-Pub 1996. PMID: 8971161.
216. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2(9):1627-36, 1996. e-Pub 1996. PMID: 9816342.
217. Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 154(6):1999-2003, 1995. e-Pub 1995. PMID: 7500444.
218. Delworth MG, Nishioka K, Pettaway CA, Gurma M, Killion JJ, von Eschenbach AC, Fidler IJ. Systemic administration of 4-amidinoindanon-1 (2-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncology 6:293-299, 1995. e-Pub 1995.
219. Morales JR, Pettaway C, Stastny P. Prediction of early kidney transplant rejection by a crossmatch with donor skin. Transplantation 48(6):951-952, 1989. e-Pub 1989. PMID: 2688207.
220. Pettaway CA, Ball EJ, Stastny P. Allogeneic lymphocyte stimulation by human spleen. Identification of cells that are very effective for presenting class II HLA antigens. Transplantation 46(6):874-8, 1988. e-Pub 1988. PMID: 2974656.
221. Pettaway CA, Freeman C, Helderman JH, Stastny P. Kidney transplant recipients with long incubation-positive antiglobulin-negative T cell crossmatches. Transplantation 44(4):529-33, 1987. e-Pub 1987. PMID: 3313840.

Invited Articles

1. Pettaway CA, Spiess PE. Multimodality treatment of penile cancer: Part 2. Urol Oncol 40(6):207-208, 2022. e-Pub 2022. PMID: 35469703.
2. Sood A, Rudzinski JK, Spiess PE, Pettaway CA. The Acute Complications After Surgery for Penile Carcinoma and Strategies for Their Management: A Systematic Review of the Literature. Semin Oncol Nurs 38(3):151285, 2022. e-Pub 2022. PMID: 35597731.
3. Pettaway CA, Spiess PE. Multimodality treatment of penile cancer: Part 1. Urol Oncol 40(5):171-172, 2022. e-Pub 2022. PMID: 35410775.
4. Bree KK, Hensley PJ, Pettaway CA. Germline Predisposition to Prostate Cancer in Diverse Populations. Urol Clin North Am 48(3):411-423, 2021. e-Pub 2021. PMID: 34210495.
5. Pettaway CA. African American and Asian males: what do we know about germline predisposition to prostate cancer. Can J Urol 26(5S2):27-28, 2019. e-Pub 2019. PMID: 31629423.
6. Chahoud J, Pickering CR, Pettaway CA. Genetics and penile cancer: Recent developments and implications. Curr Opin Urol 4(29):364-370, 2019. e-Pub 2019.
7. McCormick BZ, Pettaway CA. Insights Into the Management of Lymph Node–Positive Penile Cancer. JAMA Oncology, 2018. e-Pub 2018.
8. Pettaway CA. Usefulness of Mapping Biopsy in the Treatment of Penoscrotal Extramammary Paget's Disease. Ann Surg Oncol 24(11):3115, 2017. e-Pub 2017. PMID: 28634665.
9. Gökce MI, Sundi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. e-Pub 2017. PMID: 28417980.
10. Culp SH, Pettaway CA. Penile Cancer: New Insights into the "Way Forward" for this Rare Disease. J Urol 193(2):394-5, 2015. e-Pub 2015. PMID: 25447102.
11. Pettaway CA, Pagliaro L. Penile Squamous Carcinoma - Part II: Contemporary Management of Inguinal Region. AUA Update Series 31(16), 2012. e-Pub 2012.
12. Pettaway CA, Davis JW. Contemporary Management of Penile Carcinoma - Part I: Overview of Epidemiology, Diagnosis, Staging and Management of the Primary Tumar. AUA Update Series 31(15), 2012. e-Pub 2012.
13. Pettaway CA, Crook J, Hegarty PK, Pagliaro L. Penile Cancer Update 2011: A case-based approach. Urol Oncol 30(3):956-8, 2012. e-Pub 2012. PMID: 23218076.
14. Delacroix SE, Pettaway CA. Therapeutic strategies for advanced penile carcinoma. Curr Opin Support Palliat Care 4(4):285-92, 2010. e-Pub 2010. PMID: 20844435.
15. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 76(2 Suppl 1):S58-65, 2010. e-Pub 2010. PMID: 20691886.
16. Hegarty PK, Dinney CP, Pettaway CA. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am 37(3):421-34, 2010. e-Pub 2010. PMID: 20674697.
17. Velazquez EF, Amin MB, Epstein JI, Grignon DJ, Humphrey PA, Pettaway CA, Renshaw AA, Reuter VE, Srigley JR, Cubilla AL. Protocol for the examination of specimens from patients with carcinoma of the penis. Arch Pathol Lab Med 134(6):923-9, 2010. e-Pub 2010. PMID: 20524869.
18. Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 27(2):205-12, 2009. e-Pub 2009. PMID: 18762945.
19. Busby JE, Pettaway CA. What's new in the management of penile cancer?. Curr Opin Urol 15(5):350-7, 2005. e-Pub 2005. PMID: 16093861.
20. Izawa J, Kedar D, Wong F, Pettaway CA. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol 12 Suppl 1:24-9, 2005. e-Pub 2005. PMID: 15780161.
21. Sánchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 22(3):236-44; discussion 244-5, 2004. e-Pub 2004. PMID: 15271324.
22. Pettaway, CA, Lynch D. Contemporary Surgical Management of the Inguinal Region. AUA Update Series Lesson 33(XXI), 2002. e-Pub 2002.
23. Pettaway CA. Prognostic markers in clinically localized prostate cancer. Tech Urol 4(1):35-42, 1998. e-Pub 1998. PMID: 9568775.
24. Pettaway CA, Stephenson R, Fidler IJ. Development of orthotopic models of metastatic human prostate cancer. Cancer Bulletin 45(5):424-429, 1993. e-Pub 1993.

Review Articles

1. Fang, A, Frigo, DE, Hahn, AW, Razouki, ZA, Hwang, J, Koutroumpakis, E, Lawen, T, Smith, MR, Hamilton-Reeves, J, DiGiovanni, J, Higgason, N, Garcia, RS, Chapin, BF, Pettaway, CA, Chery, LJ, Troncoso, P, Logothetis, CJ, Daniel-MacDougall, CR, Wei, P, Gregg, JR. GLP-1 Agonist Use Among Men With Localized Prostate Cancer. Urology 201:152-158, 2025. e-Pub 2025. PMID: 40348027.
2. Fang, A, Gregg, JR, Pettaway, CA, Ma, J, Szklaruk, J, Bathala, TK, Surasi, DS, Chapin, BF. Whole-body MRI for staging prostate cancer. BJU international 135(1):13-21, 2025. e-Pub 2025. PMID: 39308142.
3. Zemp, L, Rudzinski, JK, Pettaway, CA, Nicholson, S, Spiess, PE. Management of Bulky Inguinal and Pelvic Lymph Nodes. Urologic Clinics of North America 51(3):335-345, 2024. e-Pub 2024. PMID: 38925736.
4. Giannone G, Giuliano AR, Bandini M, Marandino L, Raggi D, Earle W, Ayres B, Pettaway CA, McNeish IA, Spiess PE, Necchi A. HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Cancer Treat Rev 111:102467, 2022. e-Pub 2022. PMID: 36265336.
5. Nyame, YA, Cooperberg, MR, Cumberbatch, MG, Eggener, SE, Etzioni, R, Gomez, SL, Haiman, CA, Huang, F, Lee, CT, Litwin, M, Lyratzopoulos, G, Mohler, J, Murphy, A, Pettaway, CA, Powell, I, Sasieni, P, Schaeffer, E, Shariat, SF, Gore, JL. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European urology 82(4):341-351, 2022. e-Pub 2022. PMID: 35367082.
6. Joshi VB, Spiess PE, Necchi A, Pettaway CA, Chahoud J. Immune-based therapies in penile cancer. Nat Rev Urol 19(8):457-474, 2022. e-Pub 2022. PMID: 35851333.
7. Bree KK, Hensley PJ, Pettaway CA. Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology 163:148-155, 2022. e-Pub 2021. PMID: 34453957.
8. Jakobsen JK, Pettaway CA, Ayres B. Centralization and Equitable Care in Rare Urogenital Malignancies: The Case for Penile Cancer. Eur Urol Focus 7(5):924-928, 2021. e-Pub 2021. PMID: 34593356.
9. Chahoud J, Pickering CR, Pettaway CA. Genetics and penile cancer: recent developments and implications. Curr Opin Urol 29(4):364-370, 2019. e-Pub 2019. PMID: 31045928.
10. Leone A, Diorio GJ, Pettaway C, Master V, Spiess PE. Contemporary management of patients with penile cancer and lymph node metastasis. Nat Rev Urol. e-Pub 2017. PMID: 28401957.
11. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 51(3):271-81, 2015. e-Pub 2015. PMID: 25542058.
12. Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C. Management of advanced primary urethral carcinomas. BJU Int 114(1):25-31, 2014. e-Pub 2014. PMID: 24447439.
13. Kharadjian TB, Matin SF, Pettaway CA. Early experience of robotic-assisted inguinal lymphadenectomy: review of surgical outcomes relative to alternative approaches. Curr Urol Rep 15(6):412, 2014. e-Pub 2014. PMID: 24756453.
14. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312(5):584-93, 2006. e-Pub 2006. PMID: 16445911.
15. Sánchez-Ortiz RF, Pettaway CA. Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach. Urol Clin North Am 30(4):853-67, 2003. e-Pub 2003. PMID: 14680320.
16. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc 91(12):653-60, 1999. e-Pub 1999. PMID: 10628124.

Professional Educational Materials

1. Pettaway CA. Carcinoma of the Penis: Clinical presentation and diagnosis. Wulters Kluwer, 2019.
2. Pettaway CA. Carcinoma of the Penis: Epidemiology, Risk factors, and Pathology. Wulters Kluwer, 2019.
3. Pettaway CA. Carcinoma of the Penis: Surgical and Medical Treatment. Wulters Kluwer, 2018.
4. Hoffman K, Pagliaro L, Pettaway CA. OncoLog, MD Anderson's Report to Physicians, Penile Cancer, 2013.
5. . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Penile Cancer Guidelines. National Comprehensive Cancer Center Network, 2012.
6. . Knowing Your Options To Treat Clinically Localized Prostate Cancer, 2010.
7. . Radio Broadcast, KTSU – “Prostate Cancer in African Americans: Prevention and Detection.” Houston, TX, 2005.
8. . “Eradicating Health Care Disparities Among African American Males and Their Families Institute for Advancement of Multicultural & Minority Medicine: Mini Health Summit & Town Hall Meeting, Texas Southern University, Houston, TX, 2004.
9. . “Prostate Cancer: What You Need to Know,” Crossroads Community Church, Houston, TX, 2004.
10. . “Prostate Cancer: What You Need to Know: Prostate Outreach Project,” Holman Street Baptist Church, Houston, TX, 2004.
11. . Dia de la Mujer Hispanic Health Fair – MDACC Prostate Outreach Project Screening, Education, and Early Detection Testing, Ripley House, Houston, TX, 2004.
12. . Penile Cancer: “Evolving Indications for Inguinal Lymphadenectomy". Genitourinary Cancer Center Newsletter, 2004.
13. . “Prostate Cancer in African Americans,” KCOH Radio Station Interview, Host –Skipper Lee”, Houston TX, 2003.
14. . Houston Black and Single Magazine Article: What Every African American Should Know about Prostate Cancer, 2003.
15. Pettaway, Curtis A. Houston Style Magazine Article: M. D. Anderson Cancer Center Prostate Outreach Project Free Prostate Cancer Screenings, 2003.
16. . "Herbie Mann Memorial Blues Concert for Prostate Cancer Awareness and Early Detection Concert,“ Acres Home Multi-service Center, 2003.
17. . “Prostate Cancer,” KCOH Radio Station Interview, Host -Michael Harris, Houston TX, 2003.
18. . Prostate Cancer Blues Concert Interview, KPRC- Channel 2 News, Host – Frank Billingsley, Houston, TX, 2003.
19. . “Prostate Cancer,” “KRWP Radio Station Interview, Host- Guy Lambert, Houston, TX, 2003.
20. . “Prostate Cancer Gene Ratios May Identify Metastasis,” , 2003.
21. . "What Your Family Needs to Know About Prostate Cancer: Pipefitters Local 211- Retiree Club, Deer Park, TX, 2003.
22. . “Prostate Diseases: What You Need to Know – For Men Only, National Black Leadership Initiative on Cancer II – Houston, TX, 2002.
23. . Minority Bladder Outreach Initiative. Art Auction and Fundraiser for the Eugene Foney Bladder Cancer Treatment Fund. Groovey Grill Mansion, Houston, TX, 2002.
24. . Televised Interview, KHOU Channel 11, Coverage of 50 Hoops Basketball Tournament and Prostate Cancer Educational Event at Texas Southern University, Houston, TX, 2002.
25. . 50 Hoops Basketball Tournament and Prostate Cancer Educational Event at Texas Southern University, Houston, TX, 2002.
26. . Crossroads Show, KTRK Channel 13, “Prostate Cancer in African Americans,” Houston, TX, 2002.
27. . Prostate Cancer Education and Early Detection with American Cancer Society featuring “Conrad Johnson” Jazz Concert, Houston, TX, 2001.
28. . “Taking the Message to the Community,” for David Satcher, Surgeon General of the United States and the Honorable Sheila Jackson Lee, University of Texas M.D. Anderson Cancer Center Houston, TX, 2001.
29. . “Overview & Pathologic Insights at M. D. Anderson Cancer Center” for David Satcher, Surgeon General of the United States and the Honorable Sheila Jackson Lee, University of Texas M.D. Anderson Cancer Center Houston, TX, 2001.
30. Pettaway CA, Corral D, Grossman HB. Syllabus for AUA Course – Contemporary Management of Penile and Urethral Cancers, Chicago, IL, 2001.
31. . Prostate Cancer Awareness and Early Detection Program, Mt. Ararat Baptist Church, Houston, TX, 2000.
32. . “Prostate Cancer;” General Electric Medical Systems, 2000.
33. . Deborah Duncan Show KTRK Channel 13, "Male Health Issues- Prostate Cancer,” Houston, TX, 2000.
34. . Co-chair "Herbie Mann Jazz Caravan for Prostate Cancer Awareness and Early Detection Concert,“ Windsor Village Power Center, 2000.
35. Pettaway CA, Corral D, Grossman HB. Syllabus for AUA Course Penile Cancer, Contemporary Management of Squamous Penile Cancer, 2000.
36. . Prostate Cancer Awareness and Early Detection Program, Mt. Ararat Baptist Church, Houston, TX, 1999.
37. . Houston Chronicle Article featuring African American Hereditary Prostate Cancer Study, 1999.
38. . Ebony Magazine Feature Article: "Why Prostate Cancer is Picking On Black Men," p. 115-118, 1999.
39. . Prostate Cancer Awareness and Early Detection Program – Prairie View A&M University, Prairie View, TX, 1999.
40. . "What Your Family Needs to Know About Prostate Cancer," National Sisters Network, Inc., Breast Cancer Conference, Houston, TX, 1999.
41. . “Prostate Cancer in African Americans,” M.D. Anderson Cancer Center – Cancer Newsline, 1999.
42. . Syllabus for American Urological Association Board Review Course, Penile Cancer: Epidemiology; Diagnosis and Staging; Imaging and Treatment, Dallas, TX, 1999.
43. Pettaway CA, Corral D, Grossman HB. Syllabus for AUA Course Penile Cancer, Contemporary Management of Squamous Penile Cancer, 1999.
44. . "Preparing for a Successful Career," Sanderson Elementary School, Black History Month, H.I.S.D., Houston, TX, 1999.
45. . PBS Video: "Prostate Cancer: A Journey of Hope," Banyan Communication, Inc. Aired June, 1999.
46. . Houston Chronicle feature article regarding African American Hereditary Prostate Cancer Study: “Family Ties,” , 1998.
47. . “Prostate Cancer Education and Early Detection,” M.D. Anderson Cancer Center Outreach Initiative, Windsor Village United Methodist Church Power Center, Houston, TX, 1998.
48. . “Prostate Cancer in African Americans -Incites into Biological Differences,” Augustana Lutheran Church Men’s Organization, Houston, TX, 1998.
49. . Prostate Cancer Awareness - Channel 11 (CBS), 1998.
50. . African American Hereditary Prostate Cancer Study – Channel 11 (CBS), 1998.
51. . Syllabus for American Urological Association 93rd Annual Meeting, Management and Treatment of Advanced Carcinoma of the Prostate, San Diego, CA, 1998.
52. Pettaway, Curtis A. Radio Broadcast, KMJQ 102, Prostate Cancer in the Black Community, Houston , TX, 1998.
53. Pettaway, Curtis A. Prostate Cancer Early Detection, Shape Community Center, 100 Black Men of Metropolitan Houston, Inc., Houston, TX, 1998.
54. Pettaway, Curtis A. Prostate Cancer Early Detection, Texas State Bar Association Convention, George R. Brown Convention Center, Houston, TX, 1997.
55. . Prostate Cancer Interview, Channel 26 (FOX), 1996.
56. . Prostate Cancer Interview, Channel 13 (ABC), 1996.
57. Pettaway, Curtis A. Medical Advisor to prostate cancer dramatic production: A Matter of Manhood, Thomas Meloncon, playwright, 1996.
58. Pettaway, Curtis A. Appeared in Man-to-Man Promotional Video, for the American Cancer Society, 1996.
59. Pettaway, Curtis A. Watchful Waiting for Localized Prostate Carcinoma: Pros and Cons, UTMDACC Prostate Support Group, Houston, TX, 1996.
60. Pettaway, Curtis A. Medical Advisor in play entitled Before Time Runs Out, American Cancer Society, Atlanta, GA, 1996.
61. Pettaway, Curtis A. Minority Prostate Cancer Education and Early Detection Program, Windsor Village United Methodist Church Power Center, Houston, TX, 1996.
62. Pettaway, Curtis A. Sexual Rehabilitation Post Therapy for Prostate Cancer, Us Too Prostate Cancer Support Group, Houston, TX, 1996.
63. Pettaway, Curtis A. Sexual Rehabilitation After Therapy for Prostate Cancer, American Cancer Society, Houston, TX, 1995.
64. Pettaway, Curtis A. Detection of Circulating Prostate Cancer Cells by Polymerase Chain Reaction, M. D. Anderson Prostate Cancer Support Group, Houston, TX, 1995.
65. Pettaway, Curtis A. Update on Prostate and Testicular Cancer, British Petroleum Inc, Wellness Program, Houston, TX, 1995.
66. Pettaway, Curtis A. Prostate Diseases, Program on Epidemiology of Disease Class for the Texas Southern University, Houston, TX, 1995.
67. Pettaway, Curtis A. Educating Others About Prostate Cancer, Cancer Prevention - A Community Effort Hosted by National Black Leadership Initiative on Cancer, Houston, TX, 1994.
68. Pettaway, Curtis A. Diagnosis and Staging of Prostate Cancer, Schering International Preceptorship, Houston, TX, 1994.
69. Pettaway, Curtis A. Prostate Cancer Video: Listen Up sponsored by the Texas Cancer Council and the Texas Southern University Minority Cancer Education Center, 1993.

Other Articles

1. Pettaway C Penile Cancer: Contemporary Lymph Node Management. Practice Update, 2017.
2. Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, Ng MC, Adeyemo AA, Allison MA, Bielak LF, Chen G, Graff M, Irvin MR, Rhie SK, Li G, Liu Y, Liu Y, Lu Y, Nalls MA, Sun YV, Wojczynski MK, Yanek LR, Aldrich MC, Ademola A, Amos CI, Bandera EV, Bock CH, Britton A, Broeckel U, Cai Q, Caporaso NE, Carlson CS, Carpten J, Casey G, Chen WM, Chen F, Chen YD, Chiang CW, Coetzee GA, Demerath E, Deming-Halverson SL, Driver RW, Dubbert P, Feitosa MF, Feng Y, Freedman BI, Gillanders EM, Gottesman O, Guo X, Haritunians T, Harris T, Harris CC, Hennis AJ, Hernandez DG, McNeill LH, Howard TD, Howard BV, Howard VJ, Johnson KC, Kang SJ, Keating BJ, Kolb S, Kuller LH, Kutlar A, Langefeld CD, Lettre G, Lohman K, Lotay V, Lyon H, Manson JE, Maixner W, Meng YA, Monroe KR, Morhason-Bello I, Murphy AB, Mychaleckyj JC, Nadukuru R, Nathanson KL, Nayak U, N'diaye A, Nemesure B, Wu SY, Leske MC, Neslund-Dudas C, Neuhouser M, Nyante S, Ochs-Balcom H, Ogunniyi A, Ogundiran TO, Ojengbede O, Olopade OI, Palmer JR, Ruiz-Narvaez EA, Palmer ND, Press MF, Rampersaud E, Rasmussen-Torvik LJ, Rodriguez-Gil JL, Salako B, Schadt EE, Schwartz AG, Shriner DA, Siscovick D, Smith SB, Wassertheil-Smoller S, Speliotes EK, Spitz MR, Sucheston L, Taylor H, Tayo BO, Tucker MA, Van Den Berg DJ, Edwards DR, Wang Z, Wiencke JK, Winkler TW, Witte JS, Wrensch M, Wu X, Yang JJ, Levin AM, Young TR, Zakai NA, Cushman M, Zanetti KA, Zhao JH, Zhao W, Zheng Y, Zhou J, Ziegler RG, Zmuda JM, Fernandes JK, Gilkeson GS, Kamen DL, Hunt KJ, Spruill IJ, Ambrosone CB, Ambs S, Arnett DK, Atwood L, Becker DM, Berndt SI, Bernstein L, Blot WJ, Borecki IB, Bottinger EP, Bowden DW, Burke G, Chanock SJ, Cooper RS, Ding J, Duggan D, Evans MK, Fox C, Garvey WT, Bradfield JP, Hakonarson H, Grant SF, Hsing A, Chu L, Hu JJ, Huo D, Ingles SA, John EM, Jordan JM, Kabagambe EK, Kardia SL, Kittles RA, Goodman PJ, Klein EA, Kolonel LN, Le Marchand L, Liu S, McKnight B, Millikan RC, Mosley TH, Padhukasahasram B, Williams LK, Patel SR, Peters U, Pettaway CA, Peyser PA, Psaty BM, Redline S, Rotimi CN, Rybicki BA, Sale MM, Schreiner PJ, Signorello LB, Singleton AB, Stanford JL, Strom SS, Thun MJ, Vitolins M, Zheng W, Moore JH, Williams SM, Ketkar S, Zhu X, Zonderman AB, Kooperberg C, Papanicolaou GJ, Henderson BE, Reiner AP, Hirschhorn JN, Loos RJ, North KE, Haiman CA A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 45(6):690-6, 2013. PMID: 23583978.
3. Pettaway CA Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer. Results with pathological correlation. UroToday.com, 2007.
4. Pettaway CA Study backs lower PSA threshold for black men. Reuters Online News Article, 2006.

Editorials

1. Britton CJ, Almidani O, Baskin AS, Ritch C, Raheem O, Pettaway CA, Moses KA. Penile Cancer Survivorship: Research Gaps in Psychosocial Health and Sexual Quality of Life. Eur Urol Oncol 9(1):1-3, 2025. PMID: 41344947.
2. Pettaway CA. Editorial Comment. Urology 184:155, 2024. PMID: 38228429.
3. Pettaway CA. Risk Calculator Predicts Recurrence in Lymph Node Metastatic Penile Cancer. PracticeUpdate, 2020.
4. Pettaway CA. Penile Cancer Management in the United States: Regional Centers of Expertise are Needed!. Ann Surg Oncol 26(4):928-929, 2019. PMID: 30684158.
5. Pettaway CA. Editorial Comment. J Urol 199(6):1524-1525, 2018. PMID: 29601784.
6. Pettaway CA. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. PracticeUpdate, 2018.
7. Pettaway CA. Usefulness of Mapping Biopsy in the Treatment of Penoscrotal Extramammary Paget’s Disease. Ann Surg Oncol 24(11):3115, 2017.
8. Pettaway CA. Editorial Comment. J Urol. PMID: 27936384.
9. Pettaway CA. Editorial Comment. Urology 90:88, 2016. PMID: 27036679.
10. Wang J, Pettaway CA, Pagliaro LC. Reply. Urology 85(5):1110, 2015. PMID: 25819623.
11. Pettaway CA. Editorial comment. Urology 85(5):1101-2, 2015. PMID: 25769779.
12. Pettaway CA. Editorial Comment: Racial differences in quality of life following prostate cancer diagnosis. Urology 76(3):564; discussion 564-5, 2010. PMID: 20832603.
13. Pettaway CA. Editorial Comment: The management debate continues!. Can J Urol 16(6):4899, 2009. PMID: 20003663.
14. Pettaway CA, Horenblas S. Penile Cancer: Incremental Insights into Etiology, Diagnosis, Staging and Management. World J Urol 27(2):139, 2009. PMID: 19142645.
15. Pettaway CA. Editorial Comment: The isolated gamma probe technique for sentinel node penile carcinoma detection is unreliable. International Brazilian Journal of Urology 33(1):58-67, 2007.
16. Pettaway CA. Editorial Comment: E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes. Journal of Urology 176(4):1409-1414, 2006.
17. Pettaway CA. Editorial Comment: Penile carcinoma. Is ND: YAG Laser therapy radical enough?. Journal of Urology 168:2421, 2002.
18. Pettaway CA. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3. Journal of Urology 159:2035-40, 1998.

Abstracts

1. River-Lopez C, Sanchez-Vazquez M, Hernandez-Gonzalez A, Marco-Matinez, M, Perez-Santiago M, Figueroa-Diaz J, Lu X, Chahoud J, Zacharia N, Puras-Baez A, Pettaway CA, Martinez-Ferrer M. Human Papillomavirus Mediated Penile Cancer Overexpress NOTCH2 and JAG1. J Urol, 2022. e-Pub 2022.
2. Pettaway CA, Nicholson S, Spiess PE, Pagliaro LC, Watkin N, Barber J, Carducci MA, Trabulsi EJ, Crook JM, Rosen MA, Branney P, Oxley J, Billingham L, Burnett SM, Penegar S, Yap C, Hall EO. Trials in Progress: The international penile advanced cancer trial (InPACT): The first phase III trial for squamous qcarcinoma of the penis with regional lymph node metastases. J Clin Onc:TPS7, 2022. e-Pub 2022.
3. Chahoud J, Pham, R, Guo M, Pickering C, Qiao W, Khanna A, Netto F, Pettaway CA, Rao P. p16INK4a expression and survival outcomes in patients with penile squamous cell carcinoma: The M.D. Anderson Cancer Center Experience. J Urol 38(6 suppl), 2020. e-Pub 2020.
4. Chahoud J, Netto F, Segura RL, Cuentes ERP, Lu X, Rao P, Wistuba II, Pickering CR, Pettaway CA. Tumor immune microenvironment alterations in penile squamous cell carcinoma using multiplex immunofluorescence and image analysis approaches. J Clin Oncol 38(6 suppl), 2020. e-Pub 2020.
5. Chery L, González GMN, Gu J, Huff C, Sreekumar A, Jones J, Griffith D, Canfield S, Wang X, Huang X, Roberson P, Troncoso P, Ittmann M, Scheurer M, Ramirez MI, Pettaway C. Variant allele of SNP rs7824364 increases the risk of a positive prostate cancer biopsy: Results From The Prediction of Prostate Cancer Among African American and Puerto Rican Men (POPCAP) Study. J Urol 203(4 Suppl), 2020. e-Pub 2020.
6. McCormick B, Chahoud J, Frederico N, Rao P, Pickering C, Pettaway C. Penile Squamous Cell Carcinoma Is Genomically Similar To Other HPV-Driven Tumors. J Urol 201(Supp 4):MP73-11, 2019. e-Pub 2019.
7. McCormick B, Meissner M, Mounsif A, Slong J, Spiess P, Pettaway C. Superficial Inguinal Lymph Node Dissection Is An Effective Staging Tool For Clinically Node-Negative High Risk Penile Cancer: Results From A Multi-Institutional Review With Long-Term Follow-Up. J Urol 201(Supp 4):PD56-10, 2019. e-Pub 2019.
8. Altok M, Ward J, Chapin B, Pister L, Pettaway CA, Davis J. Cost analysis of different prostate biopsy modalities. J Urol 197(4S):e821, 2017. e-Pub 2017.
9. Sarhan A, Shang X, Tamboli P, Rao P, Pettaway C, Wang A, DePhino R, Lu X. Penile carcinoma: genetically engineered models for novel therapeutic indentification. J Urol 197(4S):e1091, 2017. e-Pub 2017.
10. Altok M, Achim M, Matin S, Pettaway CA, Davis J. A decade of robot-assisted radical prostatectomy training: time-based metrics from fellows and residents. J Urol 197(4S):e694, 2017. e-Pub 2017.
11. Jayarantna I, Matin S, Pettaway CA. Robotic Assisted Inguinal Lymphadenectomy for Penile Cancer: the MD Anderson Center Technique. The Journal of Urology 195(4):Supplement e62, 2016. e-Pub 2016.
12. Gokce M, Frost J, Roberson J, Volk R, Pettaway CA. Informed Decision Making Priot to PSA Screening: Initial Results Using the American Cancer Society (ACS) Decision AID (DA) Among A Medically Underserved Cohort. The Journal of Urology 195(4):Supplement e248, 2016. e-Pub 2016.
13. Rao P, Dhillon J, Naovarat B, Dadhania V, Wang X, Chen HC, Spiess P, Tamboli P, Pettaway CA. Prognostoc and pathologic factors determining outcome in pT2/pT3 penile carcinoma: Time for a revised staging system. The Journal of Urology 195(4):Supplement Page e98, 2016. e-Pub 2016.
14. Carmack CL, Basen-Enquist K, Shely L, Baum G, Giordano S, Rodriguez-Bigas M, Pettaway C, Demark-Wahnefried. Moves to improve lifestyle behaviors of cancer survivors and their spouses: Feasibility and preliminary results of intervention efficacy. Annals of Behavioral Medicine 45(S2):s178, 2013. e-Pub 2013.
15. Achim M, Matin S, Pettaway C, Davis DW. Robot-Assisted Radical Prostatectomy Training: 5-year Experience Using Time Metrics to Evaluate Progress. 91st Annual Meeting of the South Central Section of the AUA, 2012. e-Pub 2012.
16. Dickstein R, Mccoy J, Culp S, Pagliaro L, Pettaway C. Pre-operative Chemotherapy for Regionally Advanced Squamous Carcinoma of the Penis: the M.D. Anderson Cancer Center Experience. The Journal of Urology 187(4S, Supplement):e274, 2012. e-Pub 2012.
17. Svatek R, Culp S, Munsell M, Pettaway CA. Comparative Prognostic Ability of TNM Nodal Staging Systems and Lymph Node Density For Penile Squamous Carcinoma. The Journal of Urology 185(4):e336-e337, 2011. e-Pub 2011.
18. Pettaway CA, Nickel JC, Marberger M, Wilson TH, Rittmaster RS. Efficacy of Dutasteride in Men With Low Prostate Volume in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Study 185(4):e855, 2011. e-Pub 2011.
19. Pagliaro L, Williams D, Wen S, Thall P, Williams M, Pettaway C. Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Prospective Phase II Study. The Journal of Urology 183(4):e223, 2010. e-Pub 2010.
20. Williams M, Millikan R, Wang X, Pettaway C. Prior Definitive Local Therapy Decreases Local Symptoms/Complications Among Men With Advanced/Metastatic Prostate Cancer: Results From A Phase III Prospective Randomized Trial. The Journal of Urology 183(4):e225, 2010. e-Pub 2010.
21. Roehrborn CG, Pettaway CA, Nickel JC, Tammela TLJ, Teloken C, Somerville MC, Wilson TH, Rittmaster RS. Efficacy of Dutasteride on Benign Prostatic Hyperplasia Endpoints in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Study According to Baseline International Prostate Symptom Score and Prostate Volume. The Journal of Urology 183(4):e691, 2010. e-Pub 2010.
22. Williams M, Millikan R, Wang X, Pettaway C. The Survival Benefit of Prior Definitive Local Therapy in Men With Advanced/Metastatic Prostate Cancer:Results From A Phase III Prospective Randomized Trial. The Journal of Urology 183(4):e259, 2010. e-Pub 2010.
23. Harris LD, Song R, Pettaway CA. The Organ Environment Determines Differential Metastasis Related Gene Expression In Prostate Cancer Cell Lines LNCaP-LN3 and LNCaP-PRO5. In Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
24. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim J. Active Surveillance for Localized Prostate Cancer-A Prospective Protocol. The Journal of Urology 181(4):177, 2009. e-Pub 2009.
25. Svatek RS, Munsell MF, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston C, Spiess PE, Pettaway CA. Lymph Node Density is Strongly Associated with Disease Specific Survival in Patients Undergoing Nodal Dissection for Penile Cancer. Journal of Urology 181(4):326, 2009. e-Pub 2009.
26. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, Pettaway CA, Tammela T, Teloken C, Tindall D, Somerville M, Fowler I, Rittmaster R. Further Analyses from the Reduce Prostate Cancer Risk Reduction Trial. The Journal of Urology 181(4):555, 2009. e-Pub 2009.
27. Pettaway CA, Song R, Wang X, Liu J, McDonnell T, Black PC, Prokhorova I, Soto C, Strom S, Troncoso P. Racial Variation in the Matrix Metalloproteinase: E-Cadherin Ratio in Localized Prostate Cancer: Results from a Contemporary Matched Comparative Study. Moderated Poster Session 44: Prostate Cancer: Basic Research (IV). American Urological Association, 2008. e-Pub 2008.
28. Harris L, Song R, Pettaway CA. The Identification of Genes Associated with the Metastatic LNCaP-LN3 Prostate Cancer Cell Line. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
29. Harris L, Lee I, Dadbin A, Grossman HB, Sabichi A. Atorvastatin and Celecoxib Synergistically Suppress Human Bladder Cancer Cell Line Growth and Cell Signaling In Vivo. Proceedings in the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
30. Song R, Harris L, Pettaway C. Down-Modulation of Bcl-2 Sensitizes Metastatic LNCap-LN3 Cells to Apoptosis in Androgen Deprived Media. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
31. Pettaway CA, Song R, Lin E, Wang X, Soto C, Troncoso P. Prostate Biopsy Matrix Metalloproteinase:E-Cadherin Expression Ratio: Prognostic Significance in a Contemporary Cohort. 2008 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO), 2008. e-Pub 2008.
32. Davis JW, Pisters LL, Pettaway CA, Kamat KM, Matin S. Transfer of Robotic-Assisted Laparoscopic Prostatectomy to Multiple Trainees: A Preliminary Curriculum Based Approach. Podium Session 42: Technology and Instruments: Surgical Education & Skills Assessment (I). The Journal of Urology 179(4):624-625, Suppl 1, 2008. e-Pub 2008.
33. Suh J, Hegarty PK, Pettaway CA. Extrammary Padget’s Disease of the Penis and Scrotum: The University of Texas M.D. Anderson Cancer Center (MDACC) Contemporary Experience. The Journal of Urology 179(4):273, Suppl 1, 2008. e-Pub 2008.
34. Pettaway CA. Racial Variation in the Matrix Metalloproteinase: E-cadherin Ration in Localized Prostate Cancer. US Department of Defense (DOD) Prostate Cancer Research Program (PCRP), Innovative Minds in Prostate Cancer Today (IMPACT), 2007. e-Pub 2007.
35. Wood CG, Chang D, Wang R, Shen Y, Pettaway CA, Pisters LL, Swanson DA, Chevray P, Wen S, Madsen L, Babian R. A Randomized Phase II Trial Evaluating The Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Grafting in Patients Undergoing a Unilateral Cavernous Nerve Sparing Radical Prostatectomy for Clinically Localized PR. Moderated Poster Session 42:Prostate Cancer: Localized (IV). American Urological Association, 2007. e-Pub 2007.
36. Pettaway CA, Song R, Wang X, Liu J, McDonnell T, Black P, Prokhorova I, Soto C, Strom S, Troncoso P. Racial Variation in the Matrix Metalloproteinase: E-cadherin Ratio in Localized Prostate Cancer. The 2007 Prostate Cancer Symposium, American Society of Clinical Oncology (ASCO), 2007. e-Pub 2007.
37. Pettaway CA, Song R, Wang X, Liu J, McDonnell T, Black P, k Prokhorova I, Soto C, Strom S, Troncoso P. Racial Variation in the Matrix Metalloproteinase: E-cadherin Ratio in Localized Prostate Cancer. American Society of Clinical Oncology, 2007. e-Pub 2007.
38. Spiess PE, Brown GA, Pettaway CA, Gomez JA, Evans J, Kassouf W, Black PC, Kamat AM, Pisters LL. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Journal of Urology 175(4) Suppl:#455, 2006. e-Pub 2006.
39. Spiess PE, Bassett R, Izawa J, Kedar D, Busby JE, Wong F, Eddings T, Pettaway CA. Utility of pre-operative lymphoscintigraphy and intra-operative sentinel lymph node mapping in penile cancer: A different viewpoint. Journal of Urology 175(4) Suppl:#600, 2006. e-Pub 2006.
40. Black PC, Basen-Engquist K, Wang X, Eddings T, Pettaway CA. Testosterone, hemoglobin kinetics and quality of life during and after 12 months of post-prostatectomy androgen deprivation. Results from the Postoperative Adjuvant Androgen Deprivation (PAAD) Trial. Journal of Urology 175(4) Suppl:#684, 2006. e-Pub 2006.
41. Anai S, Wludyika P, Pendleton JM, Williams C, Nelms L, Pettaway CA, Rosser CJ. Prostate Cancer Screening and Detection in Inner-City Men. Journal of Urology 175(4) Suppl:#961, 2006. e-Pub 2006.
42. Pagliaro LC, Williams D, Daliani D, Tu SM, Kincaid M, Heller L, Pettaway C. Neoadjuvant Paclitaxel (P), Ifosfamide (I) and Cisplatin (C) Chemotherapy Prior to Inguinal/Pelvic Lymphadenectomy for Stage Tany, N2-3 M0 Squamous Carcinoma (SCC) of the Penis. Journal of Urology 175(4):#602, 2006. e-Pub 2006.
43. Pettaway CA, Pisters LL, Troncoso P, Wang X, Brown MA, Busby JE, Spiess PE, Millikan R, Logothetis C. Clinical aspects of the high risk neoadjuvant treatment model: five-year results. Journal of Urology 175(4) Suppl:#962, 2006. e-Pub 2006.
44. Leibovici D, Kassouf W, Kamat AM, Pisters LL, Pettaway CA, Dinney CPN. Transurethral tuor resection versus partial cystectomy for bladder preservation for muscle invasive cancer. J Urol (Suppl) 173(4):#1119, 2005. e-Pub 2005.
45. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. Salvage prostatectomy with bladder neck closure and continent catheterizable bladder augmentation: 31 month follow-up by patient report and incontinence symptom index. J Urol (Suppl) 173(4):#283, 2005. e-Pub 2005.
46. Spiess PE, Evans J, Kamat AM, Wood CG, Pettaway CA, Dinney CPN, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: review of The University of Texas M. D. Anderson Cancer Center experience. J Urol (Suppl) 173(4):#725, 2005. e-Pub 2005.
47. Kittles RA, Baffoe-Bonnie A, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway CA, Vijayakumar S, Bennett J, Hoke G, Weinrich S, Berg K, Furbert-Harris P, Dunston GM, Mousses S, Bailey-Wilson J, Collins FS, Powell I, Carpten JD. A screen for EphB2 germline mutations in the African American hereditary Prostate Cancer (AAHPC) families. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research 46:#1317, 2005. e-Pub 2005.
48. Song R, Pettaway CA. Modulation of Bcl-2 expression in androgen independent human prostate carcinoma LNCaP-LN3 cells leads to increased apoptosis and decreased growth. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research 46:#2729, 2005. e-Pub 2005.
49. Kim J, Vakar-Lopez F, Thall PF, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SM, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research 46:#1612, 2005. e-Pub 2005.
50. Pettaway CA, Song R, Wang X, Do KA, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression level: Prognostic significance of mRNA and protein expression among African American prostate cancer patients. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research 46:#3164, 2005. e-Pub 2005.
51. Strom SS, Yamamura Y, Pettaway CA, Logothetis CJ, Troncoso P, Do KA. Clinical, epidemiologic and molecular factos as predictors of time to biochemical failure among prostatectomy patients. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research 46:#482, 2005. e-Pub 2005.
52. Sanchez-Ortiz R, Pettaway CA, Babaian RJ, Lloreta J, Johnston D, Troncoso P. Racial differences in tumor volume and Gleason score in T1C prostate cancer: additional evidence for lowering the PSA threshold for biopsy in African American men. J Urol (Suppl) 171(4):#627, 167, 2004. e-Pub 2004.
53. Elting LS, Pettaway CA, Grossman HB, Bekele BN, Saldin KR, Dinney CPN. Relationship between postoperative in-hospital mortality and annual hospital volume of cystectomies: the effect of centers of experience. J Urol (Suppl) 169(4):#1301, 2003. e-Pub 2003.
54. Ahaghotu C, Baffoe-Bonney A, Kittles R, Pettaway C, Powell I, Royal C, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F. Clinical characteristics of the African-American hereditary prostate cancer study cohort. J Urol (Suppl) 169(4):#282, 73, 2003. e-Pub 2003.
55. Bermejo C, Sanchez-Ortiz RF, Kamat AM, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile carcinoma. J Urol (Suppl) 169(4):#683, 177, 2003. e-Pub 2003.
56. Sanchez-Ortiz RF, Yamamura Y, Frazier ML, Babaian RJ, Troncoso P, Pettaway CA, Strom S. Relationship between Cyclin D1 polymorphism and age at diagnosis in prostate carcinoma. J Urol (Suppl) 169(4):#209, 55, 2003. e-Pub 2003.
57. Song R, Sanchez-Ortiz R, Troncoso PT, Johnston DA, Strom SS, Pettaway CA. The ratio metalloproteinase to E-cadherin expression in prostatectomy specimens level distinguishes organ0-confined from advanced prostate cancer in African American men. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research 44:#995, 227, 2003. e-Pub 2003.
58. Ruiz M, Pettaway CA, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2a suppresses of prostate cancer cells by downregulating VEGF expression. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research 44:#4234, 969, 2003. e-Pub 2003.
59. Huang SF, Tamboli P, Hester G, Pettaway CA. Genital malignant melanoma: The M. D. Anderson Cancer Center Experience. J Urol (Suppl) 167(4):#614, 153, 2002. e-Pub 2002.
60. Sweeney P, Karashima T, Eve, BY, Hicklin D, Kim SJ, Fan Z, Pettaway CA, Dinney CP. Monoclonal VEGF receptor (FLK-1) antibody reduces tumorigenicity and cellular proliferation, and enhances apoptosis in orthotopic prostate cancer xenografts in nude mice. J Urol (Suppl) 167(4):# 556, 139, 2002. e-Pub 2002.
61. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens C, Wood CG, K-A D, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto CP, Fenstermacher MJ, Parker K, Merritt, Steiner MS, Logothetis CJ. Evidence that transfer of functional P53 protein results in increased apoptosis in prostate cancer. J Urol (Suppl) 167(4):# 1335, 337, 2002. e-Pub 2002.
62. Sweeney P, Millikan RE, Wood CG, Pettaway CA, Donat M, Grossman B, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic transitional cell carcinoma (TCC) of the bladder? . J Urol ((Suppl) 167(4):#1117, 283, 2002. e-Pub 2002.
63. Bielenberg R, Hida Y, Kreuter M, Pettaway C, Klagsbrun M. Semaphorin 3F overexpression inhibits tumor metastasis. Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research 43:#3339, 673, 2002. e-Pub 2002.
64. Ruiz M, Pettaway C, Song R, Troncoso P, Bar-Eli M. AP-2 transcription factor is a tumor suppressor gene in prostate cancer. Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research 43:#695, 139, 2002. e-Pub 2002.
65. Kim J, Sabichi AL, Troncoso P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Thall PF, Johnson DG, Menter SM, Lippman C, Logothetis CJ, Lieberman R. A preoperative model for testing chemopreventive agents in prostate cancer. Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research 43:#3174, 639, 2002. e-Pub 2002.
66. Pettaway CA, Song R, Maity T, Dinney CPN, Annual Meeting WCTAUA. Modulation of vascular endothelial growth factor (VEGF) expression inhibits growth and metastasis of LNCaP-LN3 cells. J Urol (Suppl) 165(5):#582, 142, 2001. e-Pub 2001.
67. Kedar D, Izawa J, Tamboli P, Ainslie N, Eddings T, Babaian RJ, Dinney CPN, Pisters LP, Pettaway CA. Intraoperative lymphatic mapping (IOLM) for squamous penile cancer: the M. D. Anderson Cancer Center prospective experience. J Urol (Suppl) 165(5):#711, 173, 2001. e-Pub 2001.
68. Slaton JW, Huang, SF, Levy DA, Pettaway CA. Lymph node-positive squamous penile carcinoma: extent of nodal involvement predicts 3-year disease-free survival. J Urol (Suppl) 165(5):#712, 173, 2001. e-Pub 2001.
69. Uehara H, Troncoso P, Johnston D, Fidler I, Dinney CPN, Pettaway CA. Interleukin-8 expression in radical prostatectomy specimens is associated with Gleason score and pathologic stage. J Urol (Suppl) 165(5):965, 234, 2001. e-Pub 2001.
70. Ruiz M, Pettaway C, Troncoso P, Bar-Eli M. AP-2 transcription factor is associated with luminal differentiation in normal prostate epithelium and it is lost in prostate cancer. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 40:#3358, 625, 2001. e-Pub 2001.
71. Williams SA, Pettaway CA, Mc Conkey DJ. Bcl-2 activates the androgen receptor in prostate cancer cell lines. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42:#2323, 433, 2001. e-Pub 2001.
72. Song R, Li E, Chen ME, Pettaway CA. Prostate specific antigen promotes growth of human prostate carcinoma LNCaP cell both in vitro and in vivo. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42:#2793, 519, 2001. e-Pub 2001.
73. SF-Y H, Slaton JW, Tamboli P, Song R, Kedar D, Sweeney P, Mian B, Pettaway CA. Development and characterization of a novel orthotopic model of penile squamous carcinoma in nude mice. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42:#4911, 914, 2001. e-Pub 2001.
74. Sweeney JP, Kedar D, Karashima T, Kim SJ, Mian B, Huang SF, Fan Z, Hicklin D, Pettaway CA, Dinney CPN. Treatment of human prostate cancer in a orthotopic murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42:#4418, 823, 2001. e-Pub 2001.
75. Karashima T, Kim SJ, Kedar D, Pettaway CA, Fan Z, Hicklin D, Dinney CPN. IMC-C225 inhibits the in vitro growth of androgen independent prostate cancer. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research 42:#4170, 777, 2001. e-Pub 2001.
76. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity or inguinal lymphadenectomy for squamous carcinoma-the M.D. Anderson Cancer Center experience. J Urol (Suppl) 63(4):#640, p. 144, 2000. e-Pub 2000.
77. Sintuu C, Inoue K, Slaton JW, Pettaway C, Dinney D, Wood C. Angiogenesis as a target for adenoviral-mediated antisense gene therapy in urologic malignancies. J Urol (Suppl) 163(4):#148, p. 34, 2000. e-Pub 2000.
78. Slaton JW, Inoue K, Morganstern N, Pheroze T, Ayala A, Dinney CPN, Pettaway CA. Metastasis-related gene expression predicts for positive inguinal lymph nodes in squamous penile carcinoma. J Urol (Suppl) 163(4):#641, p. 144, 2000. e-Pub 2000.
79. Pettaway CA, Pinto JE, Babaian RJ, Chen ME, Johnston DE, Troncoso P. Racial differences in prostate cancer foci distribution in radical prostatectomy specimens. J Urol 163(4):#1435, p. 323, 2000. e-Pub 2000.
80. Wyatt R, Wood DG, Ramirez E, Logothetis C, Pettaway CA. Race is not a prognostic factor for survival in men with androgen-independent prostate cancer. J Urol (Suppl) 163(4):#710, p. 159, 2000. e-Pub 2000.
81. Pettaway C, Song R, Li EBalbay M, Tari AM, Lopez-Berestein G, Tsan R, Radinsky R, Williams S, McConkey D, Jenster G. Androgen-independent growth of LNCaP cells that overexpress BcL-2 is mediated in part via the androgen-signaling pathway. J Urol (Suppl) 163(4):#450, p. 103, 2000. e-Pub 2000.
82. Inoue K, Eve B, Slaton JW, Perrotte P, Balbay MD, Pettaway CA, Dinney CPN. Interleukin-8 (IL-8) expression regulates metastasis in androgen-independent prostate cancer. J Urol 4(161):#200, 54, 1999. e-Pub 1999.
83. Logothetis CJ, Hossan E, Pettaway CA, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Pisters LL. AD-p53 intraprostatic gene therapy preceding radical prostatectomy (RP): An in vivo model for targeted therapy development. J Urol 4(161):#1142, 297, 1999. e-Pub 1999.
84. Kuniyasu H, Troncoso P, Inoue K, Fidler IJ, Dinney CPN, Pettaway CA. Assessment if metastasis-related gene expression in prostate biopsy specimens: A novel predictor of pathologic stage. J Urol 4(161):#911, 237, 1999. e-Pub 1999.
85. Pettaway CA, Pisters LL, Troncoso P, Finn LD, Slaton JW, Logothetis CJ. Preoperative chemotherapy (CHT) and hormonal therapy (AA) followed by radical prostatectomy (RP) for locally advanced prostate cancer (PCA). J Urol 4(161):#1154, 300, 1999. e-Pub 1999.
86. Pettaway CA, Pisters LL, Troncoso P, Finn LD, Slaton JW, Logothetis CF. Preoperative chemotherapy (CHT) and hormonal therapy (AA) followed by radical prostatectomy (RP) for locally advanced prostate cancer (PCA). American Society of Clinical Oncology 35th Annual Meeting, Atlanta, GA, 1999. e-Pub 1999.
87. Pettaway CA, Jularbal FE, Babaian RJ, Dinney CPN, Pisters LL. Intraoperative lymphatic mapping to detect inguinal metastases in penile carcinoma: Results of a pilot study. J Urol 4(161):#612, 159, 1999. e-Pub 1999.
88. Balbay MD, Juan P, Llansa N, Williams S, McConkey D, Fidler IJ, Pettaway CA. Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in vivo and in vitro". Proceedings of the 90th Annual Meeting of the American Association for Cancer Research 40:225, #1497, 1999. e-Pub 1999.

Book Chapters

1. Narayan, VM, Jayaratna, IS, Matin, S, Pettaway, CA. Robotic-Assisted Inguinal Lymphadenectomy, 399-404, 2025.
2. Zemp LW, Rudzinski JK, Pettaway CA, Nicholson S, Spiess PE. Management of Bulky Inguinal and Pelvic Lymph Nodes. In: Urol Clin North Am, 335-345, 2024.
3. Pettaway CA, Srigley JR, Brookland RK, Choyke PL, Ryan CJ, Humphrey PA, Baroca DA, Buyyounouski MK, Brimo F, Cubilla A, Fine SW, Halabi S, Hamstra DA, Kattan MW, Mason MD, Oh WK, Tambolia P, Touijer KA, Zelefsky MJ, Sandler HM, Lin DW, Amin MB. Penis. In: AJCC Cancer Staging Manual. 8th. Springer, 701-714, 2017.
4. Jayratna IS, Matin SF, Pettaway CA. Robotic-Assisted Inguinal Lymphadenectomy: The University of Texas M.D. Anderson Cancer Center Approach. In: Atlas of Robotic Urologic Surgery. 2nd. Springer, 331-337, 2017.
5. Pettaway CA, Pagliaro LC. Management of the Clinically Negative and Locally Advanced Inguinal Region in Patients with Squamous Penile Cancer. In: Management of Penile Cancer. Springer, 153-172, 2014.
6. Kuban DA, Hoffman KE, Corn P, Pettaway CA. Prostate Cancer. In: Sixty Years of Survival outcomes at The University of Texas M.D. Anderson Cancer Center. Springer, 35-44, 2013.
7. Pettaway CA, Lance RS, Davis JW. Tumors of the Penis. In: Cambell-Walsh Urology 10th Edition. 10. Saunders Elsevier, 901-933, 2012.
8. Pettaway CA, Delacroix Jr SE. Regionally Advanced Squamous Cell Carcinoma of the Penis: Current Options and Future Directions. In: Penile Cancer. Second Military Medical University Press, 124-168, 2011.
9. Hegarty PK, Pettaway CA. Future Directions, In Penile Cancer. In: Textbook of Penile Cancer. Springer, 301-330, 2011.
10. Hegarty PK, Pettaway CA. Treatment of Visceral, Unresectable, or Bulky/Unresectable Regional Metastases of Penile Cancer. In: Penile Cancer, International Consultation on Penile Cancer. Societe Internationale D’Urolgie, 2009.
11. Pettaway CA, Lynch DF, Davis JW. Tumors of the Penis. In: Campbell's Urology. 9th. Saunders Elsevier, 959-992, 2007.
12. Lynch DF, Pettaway CA. Tumors of the Penis. In: Campbell’s Urology. 8th. WB Sanders Co, 2945-2981, 2002.
13. Corral DA, Pettaway CA. Atlas of Surgical Oncology. In: Contemporary Principles and Practice, Cancer of Penis and Urethra. McGraw-Hill, 791-812, 2001.
14. Pettaway CA, Balbay MD, Grossman HB. Clinical Oncology. In: Penis and Urethra. Bermedica Production, Ltd, 1885-1905, 2000.
15. Pettaway CA Dinney CPN. Urologic and Male Genital Cancer. In: Clinical Oncology. American Cancer Society, 435-454, 2000.
16. Fidler IJ, Kuniyasu H, Greene GF, Troncoso P, Pettaway CA. Molecular diagnosis to predict the metastatic potential of human prostate cancer. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 153-161, 1999.
17. Pettaway CA von Eschenbach AC. Surgery of penile carcinoma. In: Atlas of Surgical Oncology. WB Saunders Co, 615-632, 1995.
18. Stastny P, Nunez G, Pettaway C. Class II major histocompatibility antigens of human monocytes, endothelial cells, and dendritic cells. In: HLA Class II Antigens. Springer-Verlag, 356-373, 1986.